Thorne Healthtech (THRN) 10-Q 10 Aug 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Aug. 08, 2022
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Registrant Name	Thorne HealthTech, Inc.
Entity Central Index Key	0001844280
Entity File Number	001-40826
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity Tax Identification Number	27-2877253
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	152 W. 57th Street
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10019
City Area Code	929
Local Phone Number	251-6321
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	THRN
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		52,742,179

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current Assets
Cash	$ 27,810,526	$ 51,100,915
Accounts receivable, net	10,313,916	5,285,321
Related party receivables	32,685	366,590
Inventories, net	60,471,468	41,012,124
Prepaid expenses and other current assets	1,951,700	3,494,473
Total current assets	100,580,295	101,259,423
Restricted Cash	4,900,000	4,900,000
Property and equipment, net	30,764,406	27,030,400
Operating lease right-of-use assets, net	16,203,487	17,836,756
Finance right-of-use asset	716,402	883,076
Intangible assets, net	16,089,408	6,592,316
Goodwill	16,541,041	14,440,683
Investments	1,400,000	400,000
Equity-method investments	994,534	963,685
Other related party receivables	151,300	0
Other assets	1,045,460	993,538
Total assets	189,386,333	175,299,877
Current Liabilities
Accounts payable	25,693,495	16,889,756
Accrued payroll	2,927,550	2,526,917
Other accrued expenses	2,573,760	1,144,573
Related party payable	874,870	1,634,775
Current portion of operating lease liabilities	1,599,190	2,633,236
Current portion of finance lease liabilities	391,003	413,487
Current portion of long-term debt	508,844	494,173
Total current liabilities	34,568,712	25,736,917
Long-term Liabilities
Operating lease liabilities, net of current portion	27,026,923	27,605,739
Finance lease liabilities, net of current portion	348,352	482,544
Long-term debt, net of current portion	825,488	1,083,634
Warrant liability	1,529,586	2,058,566
Total liabilities	64,299,061	56,967,400
Commitments and Contingencies (Notes 11 and 16)
Stockholders' Deficit
Additional paid-in capital	255,557,384	250,163,984
Accumulated deficit	(132,769,662)	(132,158,016)
Accumulated other comprehensive loss	(186,200)	0
Total stockholders' equity (deficit)—Thorne HealthTech, Inc.	123,128,855	118,531,510
Non-controlling interest	1,958,417	(199,033)
Total stockholders' equity	125,087,272	118,332,477
Total liabilities, convertible preferred stock and stockholders' equity	189,386,333	175,299,877
Series E Preferred Stock [Member]
Long-term Liabilities
Series E convertible preferred stock; par value $0.01, 0 shares authorized as of June 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of June 30, 2022 and December 31, 2021	0	0
Common Class B [Member]
Stockholders' Deficit
Common Stock, Value, Issued	0	0
Common Class Undefined [Member]
Stockholders' Deficit
Common Stock, Value, Issued	$ 527,333	$ 525,542

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	52,733,269	52,554,214
Common Stock, Shares, Outstanding	52,733,269	52,554,214
Series E Preferred Stock [Member]
Temporary Equity, Par or Stated Value Per Share	$ 0.01	$ 0.01
Temporary Equity, Shares Authorized	0	0
Temporary Equity, Shares Issued	0	0
Temporary Equity, Shares Outstanding	0	0
Common Class B [Member]
Common Stock, Par or Stated Value Per Share	$ 0	$ 0
Common Stock, Shares Authorized	0	0
Common Stock, Shares, Issued	0	0
Common Stock, Shares, Outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net sales		$ 56,067,826	$ 42,889,965	$ 110,736,024	$ 87,373,705
Cost of sales		24,704,294	19,994,229	49,254,885	41,240,751
Gross profit		31,363,532	22,895,736	61,481,139	46,132,954
Operating expenses:
Research and development		1,743,812	1,135,771	3,711,478	2,042,941
Marketing		17,267,461	5,045,945	22,997,714	9,284,962
Selling, general, and administrative		18,505,610	12,333,837	36,143,291	23,571,140
Write-off of acquired Drawbridge in-process research and development		0	1,563,015	0	1,563,015
Income (loss) from operations		(6,153,351)	2,817,168	(1,371,344)	9,670,896
Other (income) expense:
Interest expense, net		(31,514)	(81,256)	(61,671)	(363,901)
Guarantee fees		0	(140,407)	0	(279,271)
Change in fair value of warrant liability		594,899	317,725	528,980	(1,310,026)
Loss On Drawbridge Transaction		0	(165,998)	0	(165,998)
Other income (expense), net		(13,761)	38,143	44,094	38,143
Total other (income) expense, net		549,624	(31,793)	511,403	(2,081,053)
Income (loss) before income taxes and loss from equity interests in unconsolidated affiliates		(5,603,727)	2,785,375	(859,941)	7,589,843
Income tax expense		174,553	3,008	207,098	43,538
Net income (loss) before loss from equity interests in unconsolidated affiliates		(5,778,280)	2,782,367	(1,067,039)	7,546,305
Gain (Loss) from equity interests in unconsolidated affiliates		11,037	(3,115,658)	11,037	(3,173,106)
Net income		(5,767,243)	(333,291)	(1,056,002)	4,373,199
Net loss-non-controlling interests		(176,538)	(245,061)	(444,356)	(245,061)
Net income (loss) attributable to Thorne HealthTech, Inc.		(5,590,705)	(88,230)	(611,646)	4,618,260
Undistributed earnings (loss) attributable to Series E convertible preferred stockholders		0	(88,230)	0	4,618,260
Net income attributable to common stockholders		$ (5,590,705)	$ 0	$ (611,646)	$ 0
Earnings per share:
Basic	[1]	$ 0.11	$ 0	$ 0.01	$ 0
Diluted		$ 0.11	$ 0	$ 0.01	$ 0
Weighted average common shares outstanding:
Denominator for basic earnings (loss) per share-weighted average shares (B)	[1]	52,731,604	17,650,035	52,648,653	17,650,035
Diluted	[1]	52,731,604	17,650,035	52,648,653	17,650,035
[1] For the three and six months ended June 30, 2022, 18.1 million and 17.2 million warrants and stock-based awards, respectively, were excluded from the computation of diluted earnings (loss) per share because the effect would have been anti-dilutive under the treasury stock method

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (5,767,243)	$ (333,291)	$ (1,056,002)	$ 4,373,199
Other comprehensive loss:
Foreign currency translation adjustment, net of tax	(120,655)	0	(186,200)	0
Total other comprehensive loss	(120,655)	0	(186,200)	0
Comprehensive income (loss)	(5,887,898)	(333,291)	(1,242,202)	4,373,199
Comprehensive loss attributable to non-controlling interests	(176,538)	(245,061)	(444,356)	(245,061)
Comprehensive income (loss) attributable to Thorne HealthTech, Inc.	$ (5,711,360)	$ (88,230)	$ (797,846)	$ 4,618,260

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (unaudited) - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Noncontrolling Interest [Member]	Series E Convertible Preferred Stock [Member] Preferred Stock [Member]	Common Class B [Member] Common Stock [Member]
Beginning Balance Temporary (in Shares) at Dec. 31, 2020							27,011,500
Beginning Balance Temporary at Dec. 31, 2020							$ 133,484,531
Beginning Balance (in Shares) at Dec. 31, 2020		12,323,830						0
Beginning Balance at Dec. 31, 2020	$ (86,836,339)	$ 123,238	$ 52,451,862	$ (132,964,365)		$ (6,447,074)		$ 0
Net income/Loss	4,373,199			4,618,260		(245,061)
Currency translation adjustment	0
Common stock issued in exchange for remaining interest in consolidated affiliate (in Shares)								6,179,270
Common stock issued in exchange for remaining interest in consolidated affiliate				(6,447,074)		6,447,074
Non-controlling interest in acquired subsidiary	209,592					209,592
Stock-based compensation	534,665		534,665
Issuance of ownership interest in consolidated subsidiary	0
Ending Balance Temporary at Jun. 30, 2021							$ 133,484,531
Ending Balance Temporary (in Shares) at Jun. 30, 2021							27,011,500
Ending Balance at Jun. 30, 2021	(81,718,883)	$ 123,238	52,986,527	(134,793,179)		(35,469)		$ 0
Ending Balance (in Shares) at Jun. 30, 2021		12,323,830						6,179,270
Beginning Balance Temporary (in Shares) at Mar. 31, 2021							27,011,500
Beginning Balance Temporary at Mar. 31, 2021							$ 133,484,531
Beginning Balance (in Shares) at Mar. 31, 2021		12,323,830						6,179,270
Beginning Balance at Mar. 31, 2021	(81,619,327)	$ 123,238	52,962,384	(134,704,949)		0		$ 0
Net income/Loss	(333,291)			(88,230)		(245,061)
Currency translation adjustment	0
Non-controlling interest in acquired subsidiary	209,592					209,592
Stock-based compensation	24,143		24,143
Ending Balance Temporary at Jun. 30, 2021							$ 133,484,531
Ending Balance Temporary (in Shares) at Jun. 30, 2021							27,011,500
Ending Balance at Jun. 30, 2021	(81,718,883)	$ 123,238	52,986,527	(134,793,179)		(35,469)		$ 0
Ending Balance (in Shares) at Jun. 30, 2021		12,323,830						6,179,270
Beginning Balance (in Shares) at Dec. 31, 2021		52,554,214
Beginning Balance at Dec. 31, 2021	118,332,477	$ 525,542	250,163,984	(132,158,016)	$ 0	(199,033)
Net income/Loss	(1,056,002)			(611,646)		(444,356)
Currency translation adjustment	(186,200)				(186,200)
Other comprehensive loss	(186,200)				(186,200)
Exercise of stock options (in Shares)		179,055
Exercise of stock options	243,943	$ 1,791	242,152
Stock-based compensation	5,151,248		5,151,248
Issuance of ownership interest in consolidated subsidiary	2,601,806					2,601,806
Ending Balance at Jun. 30, 2022	125,087,272	$ 527,333	255,557,384	(132,769,662)	(186,200)	1,958,417
Ending Balance (in Shares) at Jun. 30, 2022		52,733,269
Beginning Balance (in Shares) at Mar. 31, 2022		52,728,814
Beginning Balance at Mar. 31, 2022	127,813,331	$ 527,288	252,395,590	(127,178,957)	(65,545)	2,134,955
Net income/Loss	(5,767,243)			(5,590,705)		(176,538)
Currency translation adjustment	(120,655)				(120,655)
Other comprehensive loss	(120,655)				(120,655)
Exercise of stock options (in Shares)		4,455
Exercise of stock options	20,003	$ 45	19,958
Stock-based compensation	3,141,836		3,141,836
Ending Balance at Jun. 30, 2022	$ 125,087,272	$ 527,333	$ 255,557,384	$ (132,769,662)	$ (186,200)	$ 1,958,417
Ending Balance (in Shares) at Jun. 30, 2022		52,733,269

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flows from Operating Activities
Net income/Loss	$ (1,056,002)	$ 4,373,199
Adjustments to reconcile net income to net cash (used in) provided by operating activities
Depreciation and amortization	2,865,599	2,261,969
Change in fair value of warrant liability	(528,980)	1,310,026
Non-cash lease expense	1,852,780	2,953,727
Stock-based compensation	5,151,248	534,665
Non-cash interest expense	1,285	0
Change in inventory and receivable reserves	(164,045)	(62,462)
Gain (loss) from equity interests in unconsolidated affiliate	(11,037)	3,173,106
Loss on Drawbridge transaction	0	165,998
Write-off of acquired Drawbridge in-process research and development	0	1,563,015
Other non-cash	(38,628)	0
Change in operating assets and liabilities
Accounts receivable	(5,007,492)	(3,607,072)
Related party receivables	182,605	(618,575)
Related party payables	(759,905)	401,509
Inventories	(19,321,200)	(11,411,154)
Prepaid expenses and other assets	1,515,266	(611,863)
Accounts payable and accrued liabilities	9,923,479	3,704,343
Operating lease liabilities	(1,612,862)	(3,244,257)
Net cash (used in) provided by operating activities	(7,007,889)	886,174
Cash Flows from Investing Activities
Purchase of property and equipment	(2,226,073)	(1,136,975)
Purchase of investment in unconsolidated subsidiaries	(1,000,000)	0
Purchase of license agreements	(375,000)	(563,470)
Net cash used in investing activities	(18,463,360)	(3,112,724)
Cash Flows from Financing Activities
Payments on long-term debt and finance leases	(452,989)	(324,938)
Payment of deferred offering costs	0	(2,990,760)
Debt issuance costs	(25,700)	0
Proceeds from issuance of ownership interest in consolidated subsidiary	2,601,806	0
Proceeds from exercise of stock options	243,943	0
Net cash provided by (used in) financing activities	2,367,060	(3,315,698)
Effect of exchange rate changes on cash and restricted cash	(186,200)	0
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total	(23,290,389)	(5,542,248)
Cash and restricted cash, beginning of period	56,000,915	15,262,094
Cash and restricted cash, end of period	32,710,526	9,719,846
Supplemental Disclosure of Cash Flows Information
Cash paid during the year for interest, net of interest received	77,209	371,730
Income tax paid, net of refunds received	573,372	192,618
Noncash Investing and Financing Activities
Equipment acquired through finance lease obligations	52,838	420,361
Equipment acquired through debt obligations	0	1,274,601
Right-of-use assets obtained in exchange for lease liabilities	0	2,913,002
Nutrativa LLC Acquisition [Member]
Cash Flows from Investing Activities
Acquisition, net of cash acquired	14,862,287	0
Drawbridge Health Inc [Member]
Cash Flows from Investing Activities
Acquisition, net of cash acquired	$ 0	$ 1,412,279

Description of Business and Nat

Description of Business and Nature of Operations	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Nature of Operations	1. Description of Business and Nature of Operations Thorne HealthTech, Inc. was originally incorporated under the name of Thorne Holding Corp. (the Company) and was incorporated under the laws of the state of Delaware on June 17, 2010, to acquire 100 % of the stock of Thorne Research, Inc. (Thorne Research). On November 13, 2020, the Company changed its name to Thorne HealthTech, Inc. The Company is a science-driven wellness company, pioneering innovative solutions and personalized approaches to health and wellness. The Company is building a new health category to deliver better health outcomes through a proactive, empowered approach. Its unique, vertically integrated brands, Thorne and Onegevity, provide actionable insights and personalized data, products and services that help individuals take a proactive approach to improve and maintain their health over their lifetime. By combining its proprietary multi-omics database, artificial intelligence (AI) and digital health content with its science-backed nutritional supplements, the Company delivers a total system for health and wellness.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). These condensed consolidated financial statements include the operations of the Company and all of its wholly-owned subsidiaries, as well as majority-owned subsidiaries over which the Company exercises control and, when applicable, entities for which the Company has a controlling financial interest or variable interest for which the Company is the primary beneficiary. All significant intercompany accounts and transactions have been eliminated in consolidation. On September 10, 2021, the Company approved and effected a 445 -for-1 forward stock split of the Company’s Class A common stock, Class B common stock and Series E convertible preferred stock. The par value and other terms of the common stock and preferred stock were not affected by the stock split. All related share and per share amounts have been retroactively adjusted in these condensed consolidated financial statements for all periods presented to reflect the 445 -for-1 forward stock split. Furthermore, other related information, including shares of common stock underlying the Company’s warrants, stock options and restricted stock units and their respective exercise prices have been retroactively adjusted in these condensed consolidated financial statements for all periods presented to reflect the 445 -for-1 forward stock split. Unaudited Condensed Consolidated Financial Statements The condensed consolidated balance sheet as of June 30, 2022, the condensed consolidated statements of operations, condensed consolidated statements of comprehensive income (loss) and the condensed consolidated statements of convertible preferred stock and stockholders’ equity (deficit) for the three and six months ended June 30, 2022 and 2021 and the condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021, are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair statement of the Company’s financial position as of June 30, 2022 and the results of operations and cash flows for the periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three and six months ended June 30, 2022 and 2021, are also unaudited. The condensed consolidated results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of results to be expected for the year ending December 31, 2022, nor for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2021, included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2021 , included in the Company’s Annual Report on Form 10-K filed on March 16, 2022. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. The Company bases its estimates on its historical experience and on assumptions that the Company believes are reasonable; however, actual results could significantly differ from those estimates. There have been no significant changes from the significant accounting policies disclosed in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2021 . Concentrations of Risk Credit Risk - Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash and accounts receivable. Although the Company places its cash and cash equivalents with high quality institutions, these balances can exceed federally insured limits. Concentrations of credit risk primarily relate to unsecured trade receivables. Major customers who accounted for more than 10 % of the Company’s total net receivables were as follows: June 30, December 31, 2022 2021 Emerson Ecologics, LLC 26.1 % 33.3 % Pattern Inc. 18.5 % * iHerb, Inc. 12.1 % 41.3 % * Represents less than 10% Sales - Major customers who accounted for more than 10 % of the Company’s total net sales were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Pattern Inc. 36.7 % 25.1 % 34.2 % 28.3 % Emerson Ecologics, LLC * 12.5 % * 12.3 % iHerb, Inc. * 17.5 % * 15.3 % * Represents less than 10% In-process Research and Development In-process research and development (IPR&D) was recorded at its fair value using a discounted cash flow model and was assigned to acquired research and development assets that were not fully developed as of the completion of the acquisition of Drawbridge Health, Inc. (the Drawbridge Transaction; see Note 4). IPR&D acquired in an asset purchase is capitalized on the Company’s condensed consolidated balance sheets at its acquisition-date fair value if the acquired IPR&D has alternative future use. For the IPR&D acquired from the Drawbridge Transaction it was determined that the IPR&D had no alternative future use, and therefore it was expensed immediately following the Drawbridge Transaction. Fair value measurement was classified as Level 3 under the fair value hierarchy. Fair Value Measurements Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: • Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date. • Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or that can be corroborated by observable market data. • Level 3: Significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. The carrying amounts of certain financial instruments, which include cash and cash equivalents, receivables, accounts payable and accrued expenses approximate their fair values as of June 30, 2022 and December 31, 2021 due to their short-term nature and management’s belief that their carrying amounts approximate the amount for which the assets could be sold or the liabilities could be settled. Deferred Offering Costs The Company capitalizes within other assets, certain legal, accounting and other third-party fees directly related to the Company’s in-process equity financings until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds received as a result of the offering. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written off to operating expenses. On September 22, 2021, the Company’s Registration Statement on Form S-1, as amended, was declared effective and on September 23, 2021, the Company’s common stock began trading on the Nasdaq Global Select Market, under the ticker symbol “THRN”. On September 27, 2021, the Company closed its initial public offering (IPO) of 7,000,000 shares of common stock. Through the completion of the offering, the Company incurred $ 10.0 million of offering costs, which had been capitalized prior to the completion of the offering. Upon closing of the offering, the Company reclassified these amounts to additional paid-in capital, as a reduction of the offering proceeds. Revenue Recognition The Company accounts for revenues under Financial Accounting Standards Board (FASB) Topic 606, Revenue from Contracts with Customers (ASC 606) using the following steps: • identify the contract, or contracts, with a customer; • identify the performance obligations in the contract; • determine the transaction price; • allocate the transaction price to the identified performance obligations; and • recognize revenue when, or as, the Company satisfies the performance obligations. The Company recognizes revenue at a point in time when it satisfies a performance obligation by transferring control over a product and other promised goods and services to a customer. Significant judgments made in the application of ASC 606 include determining the transaction price and the timing of transfer of control of the performance obligation (i.e., sale of product). The Company considers several factors in determining the point in time when control transfers to the customer. These factors include that legal title transfers to the customer, the Company has a present right to payment and the customer has assumed the risks and rewards of ownership. Professional/Business-to-Business (B2B) Sales: The Company sells to wholesale customers, including healthcare professionals, retail stores and through various online sites operated by authorized resellers. Certain customers resell Company products in online marketplaces, however, no inventories are held on consignment; revenue is recognized when control of the goods is transferred to these customers which is at the time of shipment. The terms of payment over the recognized receivables from distributors are less than one year, and therefore these sales do not have any significant financing components. The Company uses standard price lists in determining the transaction price, adjusted for estimates of variable consideration. Any discounts stated or implied are allocated entirely to the sole performance obligation. Direct-to-Consumer (DTC) Transaction Sales: The Company also sells direct to consumers online through a Company owned and operated website. Revenue from online sales is recognized at time of shipment of the product. In addition, the Company sells testing services and test kits. Testing services and test kits are recorded as revenue when the test results are provided to the customer. Shipping and handling costs are considered a fulfillment activity and are expensed as incurred. DTC Subscription Sales: The Company offers its customers the ability to opt into recurring automatic refills on Thorne.com and Amazon.com. Revenue is recognized under the subscription program when product is shipped to the consumer. No funds are collected at the time a consumer signs up for a subscription and the customer can cancel or modify a subscription at any time at no cost to the customer. On the Thorne.com website, customers are allowed to subscribe at a frequency of monthly, every 45 days , every 2 months , every 3 months , or every 4 months . For all these frequencies, a 10 % discount is offered on retail refill orders. For orders placed through Amazon.com, the discount ranges from 5 % to 10 % depending on the number of products to which a customer is subscribed; the average discount on Amazon for the Company’s subscriptions is approximately 6 %. The Company records revenues, net of estimated discounts. If a customer is not satisfied for any reason with a product purchased, the customer can return it to the place of purchase to receive a refund, credit, or a replacement product. The return or refund request must be submitted within 60 days of the date of purchase. The Company estimates returns and accrues for potential returns based on historical data. There are no material differences in the Company’s revenue recognition policy between the DTC subscription program and the DTC transaction program. The Company primarily sells to customers in the United States, but also sells in international markets. Regardless of customer location, customers are invoiced and payments are required to be made in U.S. dollars. The Company has elected to exclude sales and use taxes for non-exempt customers from the transaction price and, therefore, sales and use taxes are excluded from revenue. Product Returns, Sales Incentives and Other Forms of Variable Consideration In measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Such elements of variable consideration include product return rights, discounts, rebates, volume discounts and rebates, promotional offers and other marketing offers that may impact net sales. For the sale of goods with a right of return, the Company only recognizes revenue for the consideration it expects to be entitled to (considering the products to be returned) and records a sales return accrual within accrued expenses for the amount it expects to credit back its customers. Given that most product returns cannot be resold to another customer, the Company does not recognize an asset in inventory, or a corresponding adjustment to cost of sales, for the right to recover goods from customers associated with the estimated returns. The sales return accrual includes estimates that directly impact reported net sales. These estimates are calculated based on a history of actual returns and estimated future returns. In addition, as necessary, sales return accruals may be established for significant future known or anticipated events. The types of future known or anticipated events that are considered and will continue to be considered, include the Company’s decision to continue to support new and existing products. Returns are handled on a case-by-case basis, but generally returns are accepted when the customer is unsatisfied with the product. The Company has accrued an estimate for returns related to a future period. Sales returns accrued as of June 30, 2022 and December 31, 2021, were approxima tely $ 0.1 million and recorded as a reduction to net sales within the condensed consolidated statements of operations. The Company estimates sales incentives and other variable consideration using the expected value method. The variable consideration is included in the transaction price only to the extent that it is probable, in the Company's judgment, that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Under this method, certain forms of variable consideration are based on volumes of sales to the customer, which requires subjective estimates. These estimates are supported by historical results, as well as specific facts and circumstances related to the current period. A select few customers, because of their size, are offered a discount for early payment. The Company also enters into transactions and makes payments to certain of its customers related to advertising, some of which involve cooperative relationships with customers. These activities can be arranged either with unrelated third parties or in conjunction with the customer. To the extent the Company receives a distinct good or service in exchange for consideration and the fair value of the benefit can be reasonably estimated, the Company’s share of the costs of these transactions (regardless of to whom they were paid) are reflected in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations. The Company also enters into other advertising activities arranged with customers. Since these activities cannot be arranged with unrelated third parties and no distinct good or service is received in exchange for consideration, the fair value of the benefit is not reasonably estimated. The Company’s share of the costs for these transactions paid to customers are reflected as a reduction in the transaction price within net sales in the accompanying condensed consolidated statements of operations. For certain sales, the Company incurs incremental costs of obtaining the contract in the form of sales commissions. The sales commissions incurred are short-term (less than 12 months in duration) and directly correlated to the sales generated, and therefore are expensed as incurred. The following table presents disaggregated revenues by geography, as determined by the country products were shipped to: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amount Percentage Amount Percentage Amount Percentage Amount Percentage Domestic $ 52,542,648 93.7 % $ 40,845,805 95.2 % $ 105,058,997 94.9 % $ 82,725,091 94.7 % Foreign 3,525,178 6.3 % 2,044,160 4.8 % 5,677,027 5.1 % 4,648,614 5.3 % Net sales $ 56,067,826 100.0 % $ 42,889,965 100.0 % $ 110,736,024 100.0 % $ 87,373,705 100.0 % The following table presents disaggregated revenues based on sales channel: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amount Percentage Amount Percentage Amount Percentage Amount Percentage DTC subscription sales $ 9,667,533 17.2 % $ 5,546,028 12.9 % $ 18,015,429 16.3 % $ 11,026,552 12.6 % DTC transaction sales 19,214,981 34.3 % 11,486,170 26.8 % 36,677,282 33.1 % 25,409,646 29.1 % Professional/B2B 27,185,312 48.5 % 25,857,767 60.3 % 56,043,313 50.6 % 50,937,507 58.3 % Net sales $ 56,067,826 100.0 % $ 42,889,965 100.0 % $ 110,736,024 100.0 % $ 87,373,705 100.0 % Segments The Company operates in one reportable segment: the selling of innovative solutions and personalized approaches to health and wellness. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately and the allocation of resources and assessment of performance are based on the Company’s condensed consolidated operating results and where the best future opportunities arise. Recent Accounting Pronouncements – Adopted Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . In August 2020, the FASB issued this ASU to simplify the accounting for convertible instruments. This ASU also requires entities to use the if-converted method for all convertible instruments in calculating diluted earnings-per-share. This update was adopted by the Company effective January 1, 2022. The adoption did not have a material impact on its condensed consolidated financial statements. ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the Emerging Issues Task Force . In May 2021, the FASB issued this ASU to provide explicit guidance on accounting by issuers for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after the modification or exchange. This update was adopted by the Company effective January 1, 2022. The adoption did not have a material impact on its condensed consolidated financial statements. Recent Accounting Pronouncements – Not Yet Adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . In June 2016, the FASB issued this ASU to amend the current accounting guidance which requires the measurement of all expected losses to be based on historical experience, current conditions and reasonable and supportable forecasts. For trade receivables, loans and other financial instruments, the Company will be required to use a forward-looking expected loss model that reflects probable losses rather than the incurred loss model for recognizing credit losses. This ASU was amended by ASU 2019-10 to be effective for smaller reporting companies for fiscal years beginning after December 15, 2022. The Company does not believe the adoption of this ASU will have a material impact on its consolidated financial statements and related disclosures. ASU 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting . In March 2020, the FASB issued guidance providing optional expedients and exceptions to account for the effects of reference rate reform to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued. The optional guidance, which became effective on March 12, 2020 and can be applied through December 31, 2022, has not impacted the Company’s consolidated financial statements. The Company has no contracts that reference LIBOR and does not believe the adoption of this ASU will have a material impact on its consolidated financial statements and related disclosures. ASU 2021-08, Business Combinations – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . In October 2021, the FASB issued guidance intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 as if they had originated the contracts, as opposed to fair value on the date of acquisition. The standard will be effective for business combinations occurring after January 1, 2023. Early adoption is permitted. The Company is currently evaluating the impact that this guidance may have on its consolidated financial statements and related disclosures. COVID-19 Pandemic and CARES Act The full impact of the COVID-19 outbreak continues to evolve. As such, the impact of this pandemic on the Company’s financial condition is uncertain. Management is actively monitoring the impact of this virus on its financial condition, liquidity, operations, suppliers, customers and workforce. The Company's unaudited condensed consolidated financial statements presented herein reflect the latest estimates and assumptions made by management that affect the reported amounts of assets and liabilities and related disclosures as of the date of the condensed consolidated financial statements and reported amounts of revenue and expenses during the reporting periods presented. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act, was enacted. The CARES Act includes provisions relating to refundable payroll tax credits, deferment of employer-side Social Security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions and technical corrections to tax depreciation methods for qualified improvement property. The Company deferred the employer portion of payroll taxes during the year ended December 31, 2020, totaling approximately $ 1.0 million. During the year ended December 31, 2021, the Company paid $ 0.5 million of the deferred payroll taxes. As of June 30, 2022 the remaining deferred payroll taxes of $ 0.5 million will be payable by December 31, 2022 .

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	3. Related party transactions Transaction with Mitsui & Co., Ltd. and Kirin Holdings Company, Limited Series E Convertible Preferred Stock Financing On July 5, 2018, the Company issued and sold an aggregate of 27,011,500 shares of Series E convertible preferred stock to Mitsui & Co., Ltd. (Mitsui) and Kirin Holdings Company, Limited (Kirin), at a purchase price of $ 5.12 per share for aggregate gross proceeds of approximately $ 138.4 million (the Series E Financing). Immediately prior to the completion of the Company’s IPO on September 22, 2021, all outstanding shares of the Series E convertible preferred stock automatically converted on a one-to-one basis into an aggregate of 27,011,500 shares of common stock. See Note 12 for additional information related to the Series E convertible preferred stock. Kirin and Mitsui Feasibility Review Agreement On March 19, 2019, Onegevity Health, LLC (Onegevity) entered into a feasibility review agreement (Feasibility Agreement) with Kirin and Mitsui. Entities affiliated with both Mitsui and Kirin each held more than 5 % of the Company’s capital stock as of and for the years ended December 31, 2021 and 2020. Pursuant to the Feasibility Agreement, Onegevity is required to conduct a feasibility study for the successful commercialization of Onegevity’s Gutbio product (Gutbio Product) and in return each of Kirin and Mitsui paid the company $ 0.5 million (Feasibility Payment Amount). Under the Feasibility Agreement, Kirin and Mitsui may, acting jointly, any time prior to March 19, 2022, make the decision to commercialize the Gutbio Product. If they choose to commercialize the Gutbio Product, then Onegevity is required to enter into a definitive license agreement to license the Gutbio Product to Kirin and Mitsui for their exclusive use in Japan. If they do not choose to commercialize the Gutbio Product, the Feasibility Agreement requires Onegevity to issue equity securities of Onegevity to each of Kirin and Mitsui in equal amounts in consideration for the Feasibility Payment Amount. This agreement was subsequently amended on June 8, 2021 with the Amendment Agreement extending the date of determination by one year to March 19, 2023; see ‘Kirin and Mitsui Amendment Agreement’ below. Kirin and Mitsui Letter Agreements On July 5, 2018, the Company entered into a letter agreement with Kirin and Mitsui (the Thorne Japan Agreement) in connection with the Company’s Series E convertible preferred stock financing which designates Kirin and Mitsui as the Company’s exclusive strategic partners in Japan, including with respect to the commercialization in Japan of any products and services designed, developed, manufactured, marketed, provided, licensed, sold or bought by the Company from time to time. This agreement further appoints Kirin and Mitsui as the exclusive marketers and distributors of the Company’s products in Japan and provides Kirin and Mitsui with the exclusive right to conduct research and development activities related to the Company’s products in Japan, as well as manage any regulatory approvals required to market or distribute the Company’s products in Japan. This agreement also provides Kirin and Mitsui with an exclusive right of first negotiation with respect to the marketing of the Company’s products in any country in Asia, including China, ASEAN member countries, Australia, New Zealand and any other countries in which Kirin and Mitsui have an interest. This agreement expires on July 5, 2028. This agreement was subsequently amended on June 8, 2021 with the Amendment Agreement; see ‘Kirin and Mitsui Amendment Agreement’ below. Also, on July 5, 2018, the Company and Onegevity entered into a letter agreement with Kirin and Mitsui (the Onegevity Agreement) in connection with the Company’s Series E convertible stock financing which provided for certain exclusive commitments between the Company and Onegevity. Kirin and Mitsui also received a right of first negotiation with respect to any business collaboration, including with respect to Onegevity products, intellectual property, services or technology, in or with respect to Japan. The agreement also provides Kirin and Mitsui a right of first refusal over any agreement, arrangement or understanding with any third party regarding a business collaboration in the Asia Pacific region, other than Japan. This agreement does not expire. This agreement was subsequently amended on June 8, 2021 with the Amendment Agreement; see ‘Kirin and Mitsui Amendment Agreement’ below. Kirin and Mitsui Amendment Agreement On June 8, 2021, the Company entered into an Amendment Agreement with Kirin and Mitsui to amend the Feasibility Agreement, the Thorne Japan Agreement and the Onegevity Agreement. This Amendment Agreement removed the requirement from the Thorne Japan Agreement that the parties enter into separate agreements related to the exclusivity provisions discussed above and removed any provisions regarding the establishment of a joint venture in Japan. The Amendment Agreement further removed certain obsolete intercompany commitments between the Company and Onegevity, in light of the Company’s merger with Onegevity. The Amendment Agreement also amended the Onegevity Agreement to replace Onegevity with the Company as a party to the agreement. Finally, the Amendment Agreement amended the Feasibility Agreement discussed above to obligate the Company (rather than Onegevity) to issue equity securities to each of Kirin and Mitsui in the event Kirin and Mitsui elect to not commercialize the Gutbio Product by March 19, 2023. As of June 30, 2022 , no equity securities have been issued related to the Feasibility Agreement or the Feasibility Payment Amount. Kirin Juntendo Agreement On October 16, 2020, Onegevity entered into a service agreement (Juntendo Agreement) with Juntendo University and Kirin. Pursuant to the Juntendo Agreement, the Company agreed to provide DNA analysis services for up to 600 samples and in return may receive up to $ 129 thousand. During the three and six months ended June 30, 2022 , the Company recorded analysis services provided under the agreement of $ 16 thousand ( three and six months ended June 30, 2021 —$ 7 thousand and $ 15 thousand, respectively). As of June 30, 2022 , the Company has an associated related party receivable of $ 16 thousand related to the service agreement. There was no associated receivable as of December 31, 2021. Kirin and Mitsui Employment Secondments The Company is a party to secondment agreements with Kirin’s employee, Mr. Yasuhiro Oki, dated March 18, 2019 (Kirin Secondment Agreement) and Mitsui’s employee, Mr. Shuntaro Yamamoto, dated February 28, 2019 (Mitsui Secondment Agreement), under which they provide full-time services to Thorne and Thorne reimburses Kirin and Mitsui for such services. Under the Kirin Secondment Agreement and the Mitsui Secondment Agreement, the Company agreed to reimburse each of Kirin and Mitsui up to $ 120 thousand annually for such services. During the three and six months ended June 30, 2022, the Company recorded employment-related expenses o f $ 21 thousand and $ 42 thousand, respectively, related to the Kirin Secondment Agreement ( three and six months ended June 30, 2021 —$ 21 thousand and $ 42 thousand, respectively) . As of June 30, 2022 and December 31, 2021 , the Company had an associated related party payable to Kirin of $ 21 thousand r elated to the secondment reimbursement. During the three and six months ended June 30, 2022 , the Company recorded employment-related expenses of $ 30 thousand and $ 60 thousand, respectively, related to the Mitsui Secondment Agreement ( three and six months ended June 30, 2021 —$ 30 thousand and $ 60 thousand, respectively) . As of June 30, 2022 and December 31, 2021 , the Company had an associated related party payable to Mitsui of $ 30 thousand r elated to the secondment reimbursement. Kirin and Mitsui Fee Letters for $ 20.0 Million Revolver Guarantee On February 14, 2020, the Company entered into additional fee letters with Mitsui (2020 Mitsui Fee Letter) and Kirin (2020 Kirin Fee Letter), whereby both Mitsui and Kirin individually agree to guarantee half of the $ 20.0 million of borrowings under the Uncommitted and Revolving Credit Line Agreement with SMBC, dated February 14, 2020 (2020 Credit Agreement). Under the 2020 Mitsui Fee Letter and 2020 Kirin Fee Letter, the Company is required to pay each, Mitsui and Kirin, an annual fee equal to 2.00 % of their half of the $ 20.0 million guarantee. On February 12, 2021, in connection with entering into the Uncommitted and Revolving Credit Line Agreement with SMBC, dated February 12, 2021 (2021 Credit Agreement), the Company entered into new fee letters with Mitsui (2021 Mitsui Fee Letter) and Kirin (2021 Kirin Fee Letter), whereby both Mitsui and Kirin individually agreed to guarantee half of the $ 20.0 million of borrowings. Under the 2021 Mitsui Fee Letter and 2021 Kirin Fee Letter, the Company is required to pay each, Mitsui and Kirin, an annual fee equal to 1.20 % of their half of the $ 20.0 million guarantee. During the three and six months ended June 30, 2021 , the Company recorded guarantee fee expense related to the $ 20.0 million guarantees of $ 0.1 million and $ 0.2 million, respectively. On October 4, 2021, the Company repaid the $ 20.0 million of outstanding borrowings under the 2021 Credit Agreement, plus interest accrued and unpaid on the loan through the date of repayment. Upon repayment of the outstanding borrowings under the 2021 Credit Agreement, the related Kirin and Mitsui guarantees were released and terminated. See Note 10 for additional information related to the 2021 Credit Agreement. Kirin and Mitsui Fee Letters for $ 4.9 Million Letter of Credit Guarantee The Company is a party to certain fee letters with Mitsui and Kirin, under which Mitsui and Kirin provide certain guarantees of certain of the Company’s obligations. On November 30, 2018, the Company entered into fee letters with Mitsui (2018 Mitsui Fee Letter) and Kirin (2018 Kirin Fee Letter), whereby both Mitsui and Kirin individually agree to guarantee half of the $ 4.9 million letter of credit under the Reimbursement Agreement with Sumitomo Mitsui Banking Corporation (SMBC), dated October 31, 2018 (LC Reimbursement Agreement). Under the 2018 Mitsui Fee Letter and 2018 Kirin Fee Letter, the Company is required to pay each, Mitsui and Kirin, an annual fee equal to twelve-month LIBOR, plus 300 basis points of their half of the $ 4.9 million guarantee. On December 3, 2018, the Company issued an irrevocable standby letter of credit pursuant to the LC Reimbursement Agreement in the amount of $ 4.9 million to serve as security under the lease for the manufacturing facility in Summerville, South Carolina. The irrevocable standby letter of credit had an original expiration date of December 3, 2019 and automatic renewals until October 31, 2037. During the three and six months ended June 30, 2021, the Co mpany recorded guarantee fee expense of $ 41 thousand and $ 0.1 million, respectively, related to the $ 4.9 million letter of credit guarantee . On October 29, 2021, the Company deposited $ 4.9 million into a restricted interest-bearing account with SMBC to fund the standby letter of credit and release the guarantees provided by Kirin and Mitsui. As of June 30, 2022 and December 31, 2021 , the $ 4.9 million deposit is recorded as restricted cash within the condensed consolidated balance sheets. See Note 10 for additional information related to the standby letter of credit. Kirin Client Research Services Agreement On November 1, 2021, the Company entered into a feasibility review agreement with Kirin to provide research services. During the three and six months ended June 30, 2022 , the Company recognized $ 26 thousand related to these research services. As of June 30, 2022 , the Company had a related party receivable of $ 8 thousand related to these research services. Kirin and Kyowa Hakko Bio Co., Ltd. Research Agreements The Company provides certain research services under several research contracts with Kirin and Kyowa Hakko Bio Co., Ltd., a subsidiary of Kirin. During the three and six months ended June 30, 2022, the Company recognize d $ 0.1 million in revenue related to these research services. This was previously recorded as deferred revenue as of December 31, 2021, and included in other accrued expenses within the condensed consolidated balance sheets. As of June 30, 2022 , the Company had a related party payable of $ 19 thousand related to the research agreements. Other Related Party Transactions Registration Rights Agreement The Company is a party to a registration rights agreement, as amended, with certain holders of the Company’s capital stock. Under the Company’s registration rights agreement, certain holders of the Company’s capital stock, have the right to demand that the Company files a registration statement or request that their shares of the Company’s capital stock be covered by a registration statement that the Company is otherwise filing. During the three and six months ended June 30, 2022, the Company had incurre d no costs a ssociated with a registration or offering of shares of the Company’s common stock. Merger with Onegevity On January 6, 2021, the Company announced a merger with Onegevity. Paul Jacobson, the Company’s Chief Executive Officer, was also the Chief Executive Officer of Onegevity and owned 5,712 ( 4.0 %) of Onegevity’s outstanding shares. The merger transaction was approved by a majority of each of the Company’s and Onegevity’s board’s independent board members. The transaction exchanged all outstanding Onegevity equity for 14.1 % of the outstanding equity of the combined Thorne and Onegevity entity. This transaction increased Paul Jacobson’s ownership in the Company to 4.4 % based on the Company’s common stock outstanding following the merger transaction. The transaction was completed on March 3, 2021. See Note 4 for additional information related to the Onegevity merger. Merger with Drawbridge On April 21, 2021, the Company entered into a Merger Agreement with Drawbridge to acquire the majority of outstanding shares of Drawbridge, a healthcare technology company. Prior to the merger, the Company owned approximately 11.2 % of the outstanding shares of Drawbridge and accounted for the investment in Drawbridge as an equity method investment, as the Company determined it had significant influence over Drawbridge. The Company’s net equity investment was approximately $ 3.4 million as of December 31, 2020. The Company's portion of Drawbridge’s loss during 2021, up to the date of the merger, was $ 0.2 million. As of March 31, 2021 and immediately preceding the merger, the Company’s net equity investment was approximately $ 3.2 million. Under the Merger Agreement, the Company increased its ownership interest in Drawbridge by 76.3 percentage points, to a total ownership of 87.5 %. The Merger Agreement called for the payment of approximately $ 1.4 million in cash and the assumption of certain liabilities of Drawbridge. See Note 4 for additional information related to the Drawbridge merger. Supply Agreement with NR Therapeutics, LLC The Company is a party to an exclusive supply agreement dated June 5, 2020 with NR Therapeutics, LLC (NR Therapeutics) pursuant to which the Company purchases inventory of nicotinamide riboside (NR). Paul Jacobson, the Company’s Chief Executive Officer, is a member of NR Therapeutics board of directors and the Company holds a 49 % interest in NR Therapeutics. During the three and six months ended June 30, 2022 , the Company purchased inventory from NR Therapeutics totaling $ 1.5 million and $ 1.8 million, respectively ( three and six months ended June 30, 2021 —$ 1.8 million and $ 2.8 million, respectively). As of June 30, 2022 and December 31, 2021 , the Company had a related party payable of $ 0.8 million and $ 0.2 million, respectively. Letter Agreement with Tecton Group, LLC The Company is a party to a letter agreement between the Company, Tecton Group, LLC (Tecton), Kirin and Mitsui (Tecton Letter Agreement) providing the Company with, amongst other things, a right of first offer to commercialize any Tecton product or service. The Tecton Letter Agreement also provides Kirin and Mitsui, with a right of first negotiation for any commercialization of Tecton products or services in Japan. The Company’s Chief Executive Officer, Paul Jacobson, was previously a member of Tecton’s board of directors. During the six months ended June 30, 2021, the Company paid certain fees on behalf of Tecton, totaling $ 0.5 million, in exchange for additional equity interest in Tecton. As of June 30, 2022 and December 31, 2021, there were no amounts outstanding to the Company from Tecton. Strategic Supplier Agreement with Nutrativa LLC The Company is a party to a strategic supplier agreement dated August 2, 2018, as amended, with Nutrativa LLC (Nutrativa). As part of the strategic supplier agreement, the Company serves as Nutrativa’s contract manufacturer for Nutrativa’s Effusio product. The Company also provides support services including customer service, order processing, warehousing and fulfillment, safety and surveillance, production planning, finance, legal and regulatory, human resources and marketing. All manufacturing and development of Nutrativa products currently reside within the Company’s facilities located in Summerville, South Carolina. Paul Jacobson, the Company’s Chief Executive Officer, is the Chief Executive Officer of Nutrativa. During the three and six months ended June 30, 2021, the Company recognized revenue related to the supply agreement o f $ 32 thousand and $ 47 thousand, respectively. As of December 31, 2021 , the Company had recorded a related party receivable with Nutrativa of approximately $ 0.4 million. On February 28, 2022, the Company completed the purchase of all the outstanding membership interest of Nutrativa. See Note 4 for additional information related to the acquisition of Nutrativa. Investment in Oova, Inc. The Company maintains an investment in Oova, Inc. (Oova). During the three and six months ended June 30, 2022 , the Company recognized $ 24 thousand and $ 27 thousand, resp ectively, of revenue related to contractual fulfillment services that the Company provides to Oova (three and six months ended June 30, 2021 —$ 7 thousand and $ 11 thousand, r espectively). As of June 30, 2022 and December 31, 2021 , the Company had a related party receivable with Oova of approximately $ 8 thousand and $ 2 thousand, respectively. Other Related Party Transactions During the three and six months ended June 30, 2022, the Company settled a $ 43 thousand payable that was previously outstanding as of December 31, 2021 to the Chief Executive Officer, Paul Jacobson. During the three and six months ended, the Company entered into a loan agreement with the Chief Technology Officer, Scott Hurth, and established a related party receivable of $ 151 thousand, inclusive of interest receivable, included within other related party receivables on the condensed consolidated balance sheets as of June 30, 2022.

Mergers and Acquisitions

Mergers and Acquisitions	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Mergers and Acquisitions	4. Mergers and Acquisitions Onegevity Health LLC Merger On January 6, 2021, the Company announced a merger with Onegevity, a health intelligence company. As of December 31, 2020 the Company’s ownership in Onegevity was approximately 50 %. Since Onegevity’s inception in 2018, the Company determined that it has been the primary beneficiary of Onegevity and has accordingly consolidated the assets and liabilities of Onegevity in accordance with ASC 810, Consolidations . To effect the merger, the Company issued 6,179,270 shares of Class B common stock, 472,590 which were subject to time-based restrictions, to the minority shareholders of Onegevity, plus an additional 1,959,335 stock options with various strike prices to key managers of Onegevity who had stock options in Onegevity in a tax-free exchange. No cash was involved in the transaction. The shares of Class B common stock did not have voting rights among other restrictions. As part of the merger, the legal entity Onegevity Health, LLC was dissolved; its wholly-owned subsidiary, Health Elements, LLC, became a wholly-owned subsidiary of the Company. The merger did not lead to a change in control, and therefore the transaction was recorded in the equity section of the Company’s condensed consolidated balance sheets. Drawbridge Health, Inc. Merger On April 26, 2021, the Company entered into a merger agreement (the Merger Agreement) with Drawbridge Health, Inc. (Drawbridge), to acquire the majority of the outstanding shares of Drawbridge, a healthcare technology company (the Drawbridge Transaction). Prior to the merger, the Company owned approximately 11.2 % of the outstanding shares of Drawbridge and accounted for its investment in Drawbridge as an equity-method investment, because the Company determined it had significant influence over Drawbridge. The Company’s net equity investment was approximately $ 3.2 million as of March 31, 2021. Under the Merger Agreement, the Company increased its ownership of Drawbridge by 76.3 percentage points to a total ownership of 87.5 %. The Merger Agreement calls for the payment of approximately $ 1.4 million in cash and the assumption of certain liabilities of Drawbridge. The Drawbridge Transaction was accounted for as an asset acquisition because the Company concluded the assets acquired and liabilities assumed did not constitute a business under ASC 805, Business Combinations (ASC 805). The Company performed a reassessment of Drawbridge as a variable interest entity under ASC 810, Consolidation (ASC 810) and concluded Drawbridge to be a variable interest entity as of the date of the transaction. Furthermore, the Company determined it was the primary beneficiary of Drawbridge as of the transaction date. Accordingly, the Drawbridge Transaction was accounted for as an asset acquisition under ASC 810, rather than under ASC 805. Under ASC 810, the Company is required to recognize a gain (loss) on the acquisition, equal to the sum of the consideration paid, the carrying value of the existing equity-method investment and the fair value of the resulting non-controlling interest less the fair value of the net assets acquired. The Company concluded the carrying value of the Company’s existing Drawbridge investment of approximately $ 3.2 million was impaired in the second quarter of 2021 prior to the transaction and recorded a loss from equity interest in unconsolidated affiliates of approximately $ 3.0 million on the condensed consolidated statements of operations for the nine months ended September 30, 2021. Additionally, a loss on the Drawbridge Transaction of approximately $ 0.2 million was recorded during the three and six months ended June 30, 2021 within other (income) expense in the condensed consolidated statements of operations. The net tangible and intangible assets acquired and liabilities assumed, in connection with the Drawbridge Transaction were recorded based on their fair values as of the acquisition date and the value associated with in-process research and development was expensed because it was determined to have no alternative future use. The in-process research and development costs of approximately $ 1.6 million are recorded as an operating expense on the condensed consolidated statement of operations. Subsequent to the acquisition, the operations of Drawbridge were fully consolidated in the Company’s consolidated financial statements and a non-controlling interest of approximately $ 0.2 million was recorded for the 12.5 % equity interest held by other investors. The assets and liabilities acquired based on their fair value were as follows: Cash $ 11,823 Accounts receivable 8,686 Prepaid expenses and other current assets 711,389 Inventories 10,051 Property and equipment 914,716 Operating lease right-of-use assets 410,732 Intangible asset consisting of in process research and development 1,563,015 Other assets 22,782 Accounts payable ( 701,242 ) Other accrued expenses ( 864,483 ) Current portion of operating lease liabilities ( 263,509 ) Long term operating lease, net of current portion ( 147,223 ) Net assets acquired $ 1,676,737 Less: non-controlling interest ( 209,592 ) Net assets acquired by Thorne HealthTech, Inc. $ 1,467,145 Nutrativa LLC Acquisition On February 28, 2022, the Company completed the purchase of all the outstanding membership interest of Nutrativa (the Nutrativa Acquisition). Nutrativa leverages proprietary two-dimensional high-speed printing technology to develop and manufacture dissolvable supplement discs. Paul Jacobson, the co-founder, CEO and director for the Company, is also the CEO of Nutrativa. A special committee of independent directors (the “Special Committee”) of the Company's Board of Directors negotiated and approved the Nutrativa Acquisition in consultation with an independent advisory firm. The consideration provided to the unit-holders was approximat ely $ 15.4 million, comprised of $ 14.9 m illion in cash and the forgiveness of $ 0.5 million of amounts due to the Company at the time of the transaction (net of $ 18 thousand cash acquired). The Company funded the purchase with available cash on hand. The Nutrativa Acquisition will allow the Company to utilize innovative printing technology to help address consumer needs in a green, sustainable fashion, while at the same time enabling the Company to expand its portfolio of products and services into new target markets. The operations of Nutrativa have been consolidated with those of the Company beginning February 28, 2022. We have accounted for the acquisition of Nutrativa under the acquisition method of accounting in accordance with ASC 805, Business Combinations . The acquisition price has been allocated among assets acquired and liabilities assumed at fair value based on information currently available, with the excess recorded as goodwill (non-deductible for tax purposes). The goodwill recognized is attributable primarily to expected synergies to be realized by Nutrativa in leveraging the Company's existing manufacturing, distribution, research and development and marketing capabilities to efficiently scale the Nutrativa products and business. Estimates of fair value included in the condensed consolidated financial statements represent management’s best estimates and valuations. In accordance with the acquisition method of accounting, the preliminary purchase price allocation is subject to adjustment until the preliminary analysis is finalized, within a period of time not to exceed one year after the date of acquisition, or February 28, 2023. Total transaction costs incurred by the Company during the three and six months ended June 30, 2022 were $ 0.1 million and $ 0.5 million, respectively. These transaction costs were expensed as incurred and are included as a component of selling, general and administrative expense within the condensed consolidated statements of operations. The following table sets forth the preliminary allocation of the purchase price to Nutrativa’s identifiable tangible and intangible assets acquired and liabilities assumed, including measurement period adjustments: Cash $ 17,713 Accounts receivable, net 14,740 Inventories, net 274 Property and equipment, net 3,256,996 Intangible assets, net 10,200,000 Goodwill 2,100,358 Accounts payable ( 181,913 ) Other accrued expenses ( 203 ) Net assets acquired $ 15,407,965

Consolidated Variable Interest

Consolidated Variable Interest Entities	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Consolidated Variable Interest Entities	5. Consolidated Variable Interest Entities The Company consolidates variable interest entities where the Company is determined to be the primary beneficiary, under ASC 810. The Company consolidates into its condensed consolidated financial statements two legal entities (Onegevity Health, LLC and Thorne HealthTech Asia Pte, Ltd.) in which it holds a controlling interest. The Company presents non-controlling interest as a component of stockholders’ deficit on its condensed consolidated balance sheets and reports net loss - non-controlling interest in the condensed consolidated statements of operations. The Company’s acquisition or disposal of ownership interests in the variable interest entities is a reconsideration event that requires a reassessment of whether the entity continues to be a variable interest entity and whether the primary beneficiary has changed. If after making these reassessments, the primary beneficiary remains the same (i.e., a controlling financial interest is maintained) and the transaction is in the scope of ASC 810, the Company accounts for the acquisition or disposal of a non-controlling interest as an equity transaction, consistent with the principles of ASC 810-10. Any difference between the price paid and the carrying amount of the non-controlling interest is not reflected in net income, but instead reflected directly in equity. Onegevity Health, LLC . As of January 1, 2021, the Company owned 58,252 shares of Onegevity capital stock, which equated to approximately a 50 % ownership interest. After evaluating relevant factors, the Company determined that it is the primary beneficiary of Onegevity and accordingly, consolidated the assets and liabilities of Onegevity in accordance with ASC 810. During the first quarter of 2021, the Company merged with Onegevity. As part of the merger, the legal entity Onegevity Health, LLC was dissolved; its wholly-owned subsidiary, Health Elements, LLC, became a wholly-owned subsidiary of the Company. The merger did not lead to a change in control, and therefore the transaction was recorded in the equity section of the Company’s condensed consolidated balance sheets. See Note 4 for additional information related to the Onegevity merger. Thorne HealthTech Asia Pte, Ltd . On January 10, 2022, the Company entered into an agreement with Mitsui and TM HealthTech Pte. Ltd., a wholly-owned subsidiary of Mitsui, to form a joint venture entity, Thorne HealthTech Asia PTE, LTD. (Thorne Asia JV), to exclusively market, distribute and sell Thorne’s products across Singapore, Hong Kong, Taiwan, Thailand, Indonesia, Malaysia, Australia, the Philippines, Vietnam, India and New Zealand. On January 20, 2022, Thorne and Mitsui contributed approximately $ 2.7 million and $ 2.6 million, respectively, in cash and hold 51 % and 49 %, respectively, of the total issued share capital of Thorne Asia JV. After evaluating relevant factors, the Company determined that it is the primary beneficiary of Thorne Asia JV, as substantially all of the activities either involve, or are conducted on behalf of, the Company. Under ASC 810, the Company has consolidated Thorne HealthTech Asia Pte, Ltd. in its condensed consolidated financial statements for the three and six months ended June 30, 2022. The board of directors of Thorne Asia JV is composed of five directors, of which three were nominated by Thorne and two by Mitsui. Each director is appointed for a term of office of one year and will be eligible for re-election. Summary information for Thorne Asia JV, excluding intercompany activity with the Company, is included in the condensed consolidated balance sheets for the periods presented is as follows: June 30, 2022 Total assets $ 4,636,316 Less: Total liabilities 31,394 Net assets (liabilities) $ 4,604,922 The results of operations for Thorne Asia JV, excluding intercompany activity with the Company, included in the condensed consolidated statements of operations for the periods presented is as follows: Three Months Ended Six Months Ended June 30, 2022 Net sales $ 10,599 $ 16,491 Net loss ( 175,482 ) ( 546,793 ) Net loss — non-controlling interest ( 85,986 ) ( 267,929 ) Net loss attributable to Thorne HealthTech, Inc. $ ( 89,496 ) $ ( 278,864 )

Inventories, Net

Inventories, Net	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventories, Net	6. Inventories, net Inventories, net are as follows: June 30, December 31, 2022 2021 Raw materials $ 33,839,020 $ 22,620,773 Work in process 165,870 422,196 Finished goods 27,068,958 18,413,853 Reserve for slow moving and obsolete inventory ( 602,380 ) ( 444,698 ) Inventories, net $ 60,471,468 $ 41,012,124

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	7. Property and Equipment, net Property and equipment, net are as follows: June 30, December 31, 2022 2021 Machinery and equipment $ 13,914,862 $ 9,937,510 Furniture and fixtures 509,054 491,173 Office equipment 777,215 1,111,141 Leasehold improvements 19,565,760 19,431,916 Vehicles 98,282 98,282 Lab equipment 2,938,346 2,930,059 Purchased software 2,150,051 2,107,327 Internally-developed software 425,611 — Total property and equipment 40,379,181 36,107,408 Less accumulated depreciation and amortization ( 12,373,904 ) ( 11,262,651 ) In-process assets, including deposits on new equipment 2,759,129 2,185,643 Property and equipment, net $ 30,764,406 $ 27,030,400 In-process assets are stated at cost, which includes the cost of construction and other directly attributable costs. No provision for depreciation is made on in-process assets until the relevant asset s are completed and available for intended use. For the three and six months ended June 30, 2022, depreciation and amortization expense of property and equipment was $ 0.9 million and $ 1.8 million , respectively (three and six months ended June 30, 2021— $ 0.8 million and $ 1.4 million , res pectively).

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	8. Goodwill and Intangible Assets Goodwill The following table sets forth the change in the carrying amount of goodwill during the six months ended June 30, 2022: Balance as of December 31, 2021 $ 14,440,683 Acquisitions 2,100,358 Balance as of June 30, 2022 $ 16,541,041 In June 2010, the Company acquired all the outstanding shares of capital stock of Thorne Research, which is now a wholly-owned subsidiary of the Company. The Company accounted for the transaction as a business combination in accordance with ASC 805, Business Combinations , and recorded the consideration transferred, assets acquired and liabilities assumed at their fair values, resulting in the recording of goodwill of approximately $ 14.4 million. In February 2022, the Company acquired all of the outstanding ownership interests of Nutrativa, which is now a wholly-owned subsidiary of the Company. The Company accounted for the transaction as a business combination in accordance with ASC 805, Business Combinations , and recorded the consideration transferred, assets acquired and liabilities assumed at their fair values, resulting in the recording of goodwill of approximately $ 2.1 million. See Note 4 for additional information related to the acquisition of Nutrativa. Finite-lived Intangible Assets Finite-lived intangible assets are as follows: June 30, 2022 Gross Carrying Value Accumulated Amortization Net Customer relationships $ 6,500,000 $ ( 3,900,000 ) $ 2,600,000 Trade names 7,600,000 ( 6,080,000 ) 1,520,000 Existing technology/reformulations 12,400,000 ( 1,972,500 ) 10,427,500 License agreements 2,754,002 ( 1,212,094 ) 1,541,908 $ 29,254,002 $ ( 13,164,594 ) $ 16,089,408 December 31, 2021 Gross Carrying Value Accumulated Amortization Net Customer relationships $ 6,500,000 $ ( 3,737,500 ) $ 2,762,500 Trade names 8,640,000 ( 6,866,667 ) 1,773,333 Existing technology/reformulations 3,207,923 ( 2,694,590 ) 513,333 Research and development formulas 800,000 ( 800,000 ) — License agreements 8,591,822 ( 7,048,672 ) 1,543,150 $ 27,739,745 $ ( 21,147,429 ) $ 6,592,316 The Company’s intangible assets include intangible assets acquired through the acquisitions of Thorne Research in 2010 and Nutrativa in 2022. See Note 4 for additional information related to the acquisition of Nutrativa. As of June 30, 2022 and December 31, 2021, the net carrying value of acquired intangible assets was approximately $ 14.5 million and $ 5.0 million , respectively. Intangible assets also include payments under license agreements related to trademarks and content. As of June 30, 2022 and December 31, 2021 , these had a net carrying value of $ 1.5 million . When applicable, the balances as of June 30, 2022 have been reduced to reflect the impact of intangible assets when the gross carrying value has become fully amortized during the six months ended June 30, 2022. The impact of this resulted in a reduction to carrying value and accumulated amortization of $ 1.0 million to trade names, $ 1.0 million to existing technology/reformations, $ 0.8 million to research and development formulas and $ 6.2 million to license agreements. For the three and six months ended June 30, 2022, amortization expense totaled $ 0.7 million and $ 1.1 million , respectively (three and six months ended June 30, 2021— $ 0.5 million and $ 0.9 million , respectively). Future estimated amortization expense of the Company’s intangible assets as of June 30, 2022 is as follows: Remainder of 2022 $ 1,306,033 2023 2,391,234 2024 2,080,817 2025 1,551,026 2026 1,208,734 Thereafter 7,551,564 Total $ 16,089,408

Investments

Investments	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Investments	9. Investments Heart-Tech Health, Inc. On January 7, 2022, the Company entered into a Strategic Partnership Agreement with Heart-Tech Health, Inc. (Heart-Tech). Heart-Tech was formed by Dr. Suzanne Steinbaum, a leading holistic cardiologist, and has developed a program for women’s holistic health prevention. Together, the Company and Heart-Tech plans to open and operate a Thorne Lab location in New York, New York. Simultaneous to executing the Strategic Partnership Agreement with Heart-Tech, the Company made a $ 1.0 million investment in Heart-Tech through a simple agreement for future equity, or SAFE. During the three and six months ended June 30, 2022, there was no reportable activity between the Company and Heart-Tech.

Debt

Debt	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Debt	10. Debt Long-term Debt Long-term debt balances and associated interest rates and maturities are as follows: June 30, December 31, Note payable with quarterly principal and interest payments of $ 8,250 per quarter, with fixed interest of 5.44 % and maturity September 10, 2026 $ 374,888 $ 413,574 Note payable with quarterly principal and interest payments of $ 56,548 per quarter, with fixed interest of 4.89 % and maturity March 20, 2025 578,686 675,836 Note payable with quarterly principal and interest payments of $ 30,917 per quarter, with fixed interest of 6.94 % and maturity August 12, 2024 233,908 286,255 Note payable with quarterly principal and interest payments of $ 30,917 per quarter, with fixed interest of 6.94 % and maturity July 15, 2023 146,850 202,142 1,334,332 1,577,807 Less: Current portion of long-term debt ( 508,844 ) ( 494,173 ) Long-term debt, net of current portion $ 825,488 $ 1,083,634 The notes payable were issued in connection with various equipment purchases. The notes are collateralized by the original purchased equipment which had an aggregate net book value of $ 1.7 million as of June 30, 2022. Loan Agreement On April 8, 2022, the Company entered into a Loan Agreement with Bank of America, N.A. (Loan Agreement), with an effective date of March 31, 2022. Under the terms of the Loan Agreement, Bank of America N.A. (BofA) provided a revolving line of credit to the Company in the amount of $ 15.0 million (the Line of Credit). Under the Loan Agreement, the Company may repay principal amounts and reborrow them as necessary until March 31, 2027 (the Expiration Date). Outstanding borrowings under the Loan Agreement will be subject to interest at a rate equal to the Bloomberg Short-Term Bank Yield Index rate (BSBY), plus 1.50 %, adjusted on the first day of each month (the Adjustment Date). Interest is calculated on the basis of a 360-day year and the actual number of days elapsed. The Company agreed to pay interest on any outstanding borrowings beginning April 30, 2022, and then on the same day of each month thereafter, until all principal outstanding is repaid under the Loan Agreement. Should the first day of a calendar month fall on a day that is not a banking day, then the Adjustment Date shall be the first banking day immediately following thereafter. The Line of Credit is subject to an Unused Commitment Fee equal to 0.2 % per year. The Unused Commitment Fee was due on May 1, 2022, and on the same day each following quarter until the expiration of the Loan Agreement. As a sub-facility under the Line of Credit, the Lender has provided up to $ 6.0 million in commercial and standby letters of credit (the Letters of Credit). Any outstanding and undrawn Letters of Credit shall be reserved under the Line of Credit and such amount shall not be available for borrowings. Letters of Credit issued under the Loan Agreement are subject to BofA’s customary issuance, presentation, amendment and other processing fees and other standard costs and charges. All borrowings under the Loan Agreement are guaranteed by Thorne Research, Inc., a subsidiary of the Company, and secured by substantially all personal property of the Company, including depository accounts, receivables, inventory, equipment, general intangibles and other unencumbered assets. Upon the occurrence of any default, all outstanding and unpaid amounts, including unpaid interest, fees, or costs will bear interest at a rate equal the then effective interest rate, plus 6.0 %. The Loan Agreement is subject to customary covenants, including the following financial covenants: i. Consolidated Total Leverage to EBITDA Ratio: The Company has agreed to maintain a consolidated Funded Debt to EBITDA not exceeding 2.5 :1.0. Funded Debt is defined as all outstanding liabilities for borrowed money (including any outstanding Letters of Credit) and other interest-bearing liabilities, including current and long-term debt, less the non-current portion of Subordinated Liabilities. Funded Debt shall not include operating lease liabilities. ii. Consolidated Fixed Charge Coverage Ratio: The Company has agreed to maintain a consolidated Fixed Charge Coverage Ratio of at least 1.25 :1.0. Consolidated Fixed Charge Coverage Ratio is defined as the ratio of (a) consolidated EBITDA, less the amount of unfinanced capital expenditures, plus rental expense for such period, to (b) the sum of Federal/state/local taxes, interest expense, lease expense, rent expense, the current portion of long term debt, the current portion of finance lease obligations and any Restricted Payments incurred or made during the period. As of June 30, 2022 , the Company has not drawn any amounts or initiated any borrowings and the full $ 15.0 million is available under the Loan Agreement. Credit Facilities On February 12, 2021, the Company entered into the 2021 Credit Agreement to refinance and replace the 2020 Credit Agreement, entered into on February 14, 2020. On October 4, 2021, the Company repaid the $ 20.0 million of outstanding borrowings under the 2021 Credit Agreement, plus interest accrued and unpaid on the loan through the date of repayment. Upon repayment, the 2021 Credit Agreement was terminated. The Company incurred incremental fees related to the payoff totaling $ 7 thousand. T he 2021 Credit Agreement was guaranteed by two significant Company stockholders, Kirin and Mitsui. Each stockholder guaranteed 50 % of the total amount of the loan, or $ 10 .0 million. Under the respective 2021 Fee Letters, the Company has agreed to reimburse Mitsui and/or Kirin in cash for any amounts that Mitsui and/or Kirin pays under its respective guarantee of the 2021 Credit Agreement. However, if the Company is unable to reimburse such amounts wholly or partially to Mitsui and/or Kirin, then the Company and Mitsui and/or Kirin may agree to deem such unreimbursed amounts to be made for the Company’s benefit in consideration for its debt or equity securities on terms reasonably satisfactory to Mitsui and/or Kirin and the Company. The guarantee fee during the period of February 14, 2020 through February 13, 2021 was calculated as 2.00 % of the outstanding borrowings under the Credit Agreements, to be paid by the borrower on an annual basis. Beginning February 12, 2021, the guarantee fee was calculated as 1.20 % of the outstanding borrowings under the Credit Agreements. During the three and six months ended June 30, 2021 , the Company recorded $ 0.1 million and $ 0.2 million, respectively, of related expense, which are included within guarantee fees in the condensed consolidated statements of operations. Upon repayment of the outstanding borrowings under the 2021 Credit Agreement, the related Kirin and Mitsui guarantees were released and terminated. Standby Letter of Credit In 2018, an irrevocable standby letter of credit was issued by a bank on the Company’s behalf as required by the landlord of the South Carolina production facility and guarantees were issued by related parties. The standby letter of credit was for $ 4.9 million and had an original expiration date of December 3, 2019 , with automatic renewals until October 31, 2037 . The standby letter of credit is guaranteed 50 % by Kirin and Mitsui, to whom the Company pays an annual guarantee fee. Under the respective 2018 Fee Letters, the guarantee fee is based on the 12-month USD LIBOR rate, plus 3 % on the amount of the guarantee. The letter of credit has an annual fee of $ 20 thousand. On October 29, 2021, the Company deposited $ 4.9 million into a restricted interest-bearing account with SMBC to fund the standby letter of credit and release the guarantees provided by Kirin and Mitsui. During the three and six months ended June 30, 2021, the Com pany incurred total guarantee fee expense for the standby letter of credit of $ 41 thousand and $ 0.1 million, respectively, wh ich has been included in guarantee fees in the condensed consolidated statements of operations .

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	11. Leases The Company leases real estate, vehicle and equipment for use in its operations. The Company’s leases generally have lease terms of one to 30 years, some of which include options to terminate, or to extend leases. The Company includes options that are reasonably certain to be exercised as part of the determination of lease terms. The Company may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within operating leases. In addition to base rent payments, the leases may require the Company to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. On January 26, 2021, the Company entered into a five-year lease agreement for 115,500 square feet within a 136,500 square foot building for the Company's fulfillment and distribution operations, located in Summerville, South Carolina. Rent was abated for the first three months while the Company installed racking, packing stations and other required equipment, prior to the Company's shipping operations to this facility. This lease terminates in July 2026 . The lease has two renewal options for three years each. The Company has funded a customary security deposit of $ 0.1 million upon execution of the lease, which has been recorded within other assets on the condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. On July 28, 2021, the Company entered into a lease agreement for a 360,320 square foot industrial building for the Company's finished goods warehousing and shipping operations, located in Summerville, South Carolina. The building is currently under construction and the lease will commence on the date of which the landlord completes construction of the facility and required tenant improvements, currently estimated to be during the first quarter of 2023 and will terminate upon the thirteenth anniversary of the commencement date. The lease has one renewal option for a five-year term. The lease provides for an allowance for tenant improvements of up to $ 1.3 million. The annual base rent for the first year will be $ 2.0 million and is subject to an annual escalation of 2.0 % on each anniversary. The Company has funded a customary security deposit of $ 0.3 million upon execution of the lease which has been recorded within other assets on the condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. On March 10, 2022, the Company amended the lease agreement for its headquarters in New York, New York. The amended agreement grants an additional right-of-use (“second substitute premises”) to the Company in the future following the expiration of its current lease. The second substitute premises are estimated to be substantially complete during the third quarter of 2022. The amendment will commence on September 12, 2022 and will terminate on the five year anniversary of the rent commencement date. The balances for the operating and finance leases where the Company is the lessee are presented as follows within the condensed consolidated balance sheets: June 30, December 31, Operating lease: Operating lease right-of-use assets, net $ 16,203,487 $ 17,836,756 Current portion of operating lease liabilities 1,599,190 2,633,236 Operating lease liabilities, net of current portion 27,026,923 27,605,739 Total operating lease liabilities $ 28,626,113 $ 30,238,975 Finance lease: Finance lease right-of-use assets $ 716,402 $ 883,076 Current portion of finance lease liabilities 391,003 413,487 Finance lease liabilities, net of current portion 348,352 482,544 Total finance lease liabilities $ 739,355 $ 896,031 The components of lease expense are as follows within the condensed consolidated statements of operations: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Operating lease expense: Operating lease cost (1) $ 1,461,356 $ 1,369,459 $ 2,922,711 $ 2,602,167 Finance lease expense: Amortization of leased assets 107,112 94,418 219,512 168,333 Interest on lease liabilities 10,459 13,748 22,047 25,048 Total lease expense $ 1,578,927 $ 1,477,625 $ 3,164,270 $ 2,795,548 (1) Includes short-term leases and variable lease costs, which are immaterial. The weighted-average remaining lease term and weighted-average discount rate as of June 30, 2022 and December 31, 2021, were as follows: June 30, December 31, Weighted average remaining lease term (years) Operating leases 13.93 years 13.73 years Finance leases 2.01 years 2.33 years Weighted average discount rate applied Operating leases 8.9 % 9.2 % Finance leases 5.9 % 6.1 % Supplemental cash flow information related to leases where the Company is the lessee is as follows: Six Months Ended June 30, 2022 2021 Operating cash outflows from operating leases $ 2,902,305 $ 3,244,257 Operating cash outflows from finance leases (interest payments) $ 22,047 $ 25,048 Financing cash outflows from finance leases $ 209,514 $ 171,734 Leased assets obtained in exchange for finance lease liabilities $ 52,838 $ 420,361 Leased assets obtained in exchange for operating lease liabilities $ — $ 2,913,002 As of June 30, 2022, the maturities of the operating and finance lease liabilities are as follows: Operating Leases Finance Leases Remainder of 2022 $ 2,218,628 $ 233,900 2023 3,497,422 343,422 2024 3,589,920 157,455 2025 3,559,583 22,189 2026 3,325,639 38,944 Thereafter 35,705,779 — Total lease payments $ 51,896,971 $ 795,910 Less: imputed interest 23,270,858 56,555 Total present value of lease liabilities $ 28,626,113 $ 739,355 Less: current portion of lease liabilities 1,599,190 391,003 Long-term portion of lease liabilities $ 27,026,923 $ 348,352 In 2016, the Company entered into a new lease agreement for office, warehouse and production space in Summerville, South Carolina. The Company was required to provide the landlord with a $ 4.9 million irrevocable letter of credit as a security deposit (see Note 10). The required security deposit may be reduced upon the attainment of certain EBITDA levels.

Convertible Preferred Stock and

Convertible Preferred Stock and Stockholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Convertible Preferred Stock and Stockholders' Equity (Deficit)	12. Convertible Preferred Stock and Stockholders’ Equity (Deficit) On July 5, 2018, the Company issued 27,011,500 Series E convertible preferred stock to Kirin and Mitsui for $ 138.4 million. A summary of the significant rights and privileges of the Series E convertible preferred stock is as follows: Conversion - Each share of Series E preferred stock is convertible at the option of the holder into common stock on a one-for-one basis. Each share of Series E preferred stock shall automatically be converted into shares of common stock at the then effective conversion price immediately after the consummation of a qualified public offering. Additionally, each share of preferred stock is automatically converted immediately upon the conversion or vote to convert by the holders of a majority of the then outstanding preferred stock. Liquidation - Upon any liquidation, dissolution, or winding-up of the business, the assets of the Company available for distribution to its stockholders shall be distributed first to the holders of shares of Series E convertible preferred stock up to their original issue prices. Voting Rights - The holder of each share of preferred stock shall be entitled to vote on all matters and shall be entitled to that number of votes equal to the total number of shares of common stock into which the preferred stock are convertible. Dividends - In the event the Board of Directors declares the payment of dividends, they shall be distributed first to the holders of shares of Series E convertible preferred stock up to their original issue prices. Thereafter, the amounts remaining shall be distributed pro rata based on the number of shares of common stock then held by each shareholder (assuming conversion of all outstanding shares of Series E convertible preferred stock into common stock). The Company’s Series E convertible preferred stock has been classified as temporary equity on the accompanying condensed consolidated balance sheets in accordance with authoritative guidance for the classification and measurement of redeemable securities. Upon certain change in control events outside of the Company’s control, including liquidation, sale, or transfer of control of the Company, holders of the Series E convertible preferred stock can cause its redemption. The Company has determined not to adjust the carrying values of the Series E convertible preferred stock to the liquidation preferences of such shares because the Series E convertible preferred stock is not currently redeemable and not probable of becoming redeemable due to the uncertainty of whether or when the contingent events would occur. Immediately prior to the completion of the Company’s IPO on September 22, 2021, all outstanding shares of the Series E convertible preferred stock automatically converted on a one-to-one basis into an aggregate of 27,011,500 shares of common stock. As of June 30, 2022 and December 31, 2021 , there were no shares of Series E convertible preferred stock outstanding

Warrants

Warrants	6 Months Ended
	Jun. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Warrants	13. Warrants On October 10, 2018, the Company issued to Kirin and Mitsui each 2,225,000 warrants, for a total of 4,450,000 warrants, to purchase the Company’s common stock. The warrants have an exercise price of $ 5.12 and an expiration date of October 11, 2028 . In July 2020, each shareholder exercised 2,168,485 warrants for a total of $ 22.2 million in gross proceeds. As of June 30, 2022 and December 31, 2021 , 113,030 , of the original 4,450,000 warrants, remain outstanding. These warrants are classified as equity within the condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. On June 23, 2010, the Company issued 2,532,000 warrants to a related-party stockholder, with a strike price of $ 6.74 and an original expiration date of June 23, 2020 . In May 2019, the Board of Directors extended the term of the warrants for an additional 10 years to June 23, 2030. As of June 30, 2022 and December 31, 2021 , none of the 2,532,000 warrants have been exercised and all common stock warrants remained outstanding. These warrants are classified as equity within the condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. On May 10, 2011, the Company issued 453,455 warrants to purchase common stock to a related-party stockholder, with a strike price of $ 6.74 per warrant. In May 2019, the Board of Directors extended the term of the warrants for an additional 10 years to June 23, 2030. The extension was determined by management to be a modification of the warrant. Due to these warrants containing certain down-round protections, which are not associated with the underlying Company’s equity that may trigger in the event of a modification of certain other outstanding warrant instruments, the Company has classified these warrants as liabilities within the condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. The warrant liability is remeasured at fair value at each reporting date and has a fair value of $ 1.5 million as of June 30, 2022 and $ 2.1 million as of December 31, 2021. To calculate the fair value of the warrants, certain assumptions were made, including the fair market value of the underlying common stock, risk-free interest rate, volatility and remaining contractual life. Changes to the assumptions could cause significant adjustments to the valuation. Due to the fact that the Company had no publicly available stock price information prior to the IPO and limited publicly available stock price information subsequent to the IPO, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available. The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of the grant for treasury securities of similar maturity or expected term. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. The Black-Scholes model was used to value the liability-classified warrants. The following assumptions were used: June 30, December 31, 2022 2021 Fair market value $ 4.84 $ 6.21 Exercise Price $ 6.74 $ 6.74 Term (years) 8.0 8.5 Volatility 75 % 75 % Annual dividend — — Risk-free interest rate 3.01 % 1.48 % The fair value of financial instruments measured on a recurring basis is as follows: June 30, 2022 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 1,529,586 — 1,529,586 $ — December 31, 2021 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 2,058,566 — — $ 2,058,566 Changes in the ability to observe valuation inputs may result in a reclassification of levels within the fair value hierarchy. The following table summarizes the changes in Level 3 measurement and transfers in or out of the Level 3 fair value hierarchy, for the warrant liability, during the six months ended June 30, 2022: Warrant Balance as of December 31, 2021 $ 2,058,566 Change in fair value during the three months ended March 31, 2022 65,919 Transfer to level two during the three months ended June 30, 2022 ( 2,124,485 ) Balance as of June 30, 2022 $ —

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	14. Stock-based Compensation Prior to the Company’s IPO, the Company’s Board of Directors adopted, and the stockholders approved the Company’s 2021 Equity Incentive Plan (2021 Plan). The 2021 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to Company employees and parent and subsidiary corporations’ employees, and for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards (RSAs), restricted stock units (RSUs) and performance awards to employees, directors and consultants and parent and subsidiary corporations’ employees and consultants. On January 26, 2022, in accordance with the 2021 Plan's adjustment provisions, the Company increased the share reserve by 2,627,710 shares, as registered on Form S-8 and filed with the SEC on January 26, 2022. As of June 30, 2022 , there were 1,359,972 shares available for issuance under the 2021 Plan. Stock-based Compensation Expense Stock-based compensation expense for the periods indicated is as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Stock options $ 237,786 $ 24,143 $ 475,572 $ 534,665 Restricted stock units 2,904,050 — 4,675,676 — Total stock-based compensation expense $ 3,141,836 $ 24,143 $ 5,151,248 $ 534,665 Stock Options The following table summarizes stock option activity for the six months ended June 30, 2022: Options Outstanding Weighted- Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic (1) Outstanding as of January 1, 2022 9,699,656 $ 5.28 6.22 $ 12.3 Granted — - Exercised ( 179,055 ) 1.36 Cancelled/forfeited — - Outstanding as of June 30, 2022 9,520,601 5.35 5.58 3.6 Vested and expected to vest as of June 30, 2022 9,520,601 $ 5.35 5.58 $ 3.6 Exercisable as of June 30, 2022 1,690,381 $ 2.71 2.42 $ 3.6 (1) Aggregate intrinsic value is presented in millions of U.S. dollars and represents the difference between the closing fair value of the underlying common stock and the exercise price of outstanding, in-the-money options on the date of measurement. The following table summarizes additional information related to stock options for the periods presented: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Weighted-average grant date fair value of stock options granted (1) N/A N/A N/A N/A Grant date fair value of stock options vested (1)(2) N/A N/A N/A N/A Intrinsic value of stock options exercised (3) $ 8,133 N/A $ 857,460 N/A (1) The three and six months ended June 30, 2021 excludes 1,959,335 stock options issued in exchange for outstanding stock options of Onegevity, in connection with the merger. The stock option exchange was determined to be materially a “like-for-like” transaction and there was no incremental stock compensation expense recorded by the Company. The Company compared the fair value of the stock options immediately before and after the exchange and determined that the exchange did not result in incremental compensation expense. (2) During the three and six months ended June 30, 2022 and 2021, there were no stock options that vested. (3) Shares of the Company’s common stock, traded under the symbol “THRN,” have been publicly traded since September 23, 2021, when the Company’s common stock was listed and began trading on the Nasdaq Global Select Market (the “Nasdaq”). No market for the Company’s stock existed prior to September 23, 2021. There were no stock option exercises prior to the IPO date. As of June 30, 2022 , the unrecognized stock-based compensation expense related to outstanding stock options was approximately $ 0.2 million and is expected to be recognized as expense over the next three months . Restricted Stock Units The following table summarizes RSU activity for the six months ended June 30, 2022: Number Weighted- Outstanding as of January 1, 2022 3,406,760 $ 9.82 Granted 2,217,248 6.91 Released — — Cancelled/forfeited ( 5,000 ) 8.40 Outstanding as of June 30, 2022 5,619,008 $ 8.67 Vested and expected to vest as of June 30, 2022 5,619,008 $ 8.67 The following table summarizes additional information related to RSUs for the periods presented: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Weighted-average grant date fair value of RSUs granted (1) $ 6.91 N/A $ 6.91 N/A Grant date fair value of RSUs vested (1)(2) N/A N/A N/A N/A Intrinsic value of RSUs released (1)(2) N/A N/A N/A N/A (1) The three and six months ended June 30, 2021 excludes 472,590 R SUs issued in exchange for outstanding profits interest units held by employees of Onegevity, in connection with the merger. The RSU exchange was determined to be materially a “like-for-like” transaction and there was no incremental stock compensation expense recorded by the Company. The Company compared the fair value of the RSUs immediately before and after the exchange and determined that the exchange did not result in incremental compensation expense. (2) During the three and six months ended June 30, 2022 and 2021, there were no RSUs that vested or released. As of June 30, 2022, the unrecognized stock-based compensation expense related to outstanding RSUs was approximately $ 42.3 million and is expected to be recognized as expense over approximately 3.6 years.

Basic and Diluted Net Income (L

Basic and Diluted Net Income (Loss) per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Basic and Diluted Earnings (Loss) per Share	15. Basic and Diluted Earnings (Loss) per Share Basic earnings (loss) per share is calculated by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common stock and common stock equivalents outstanding for the period. For periods in which the Company incurs a net loss, outstanding common stock equivalents are not included in the calculation of diluted earnings (loss) per share as their effect is anti-dilutive. Accordingly, basic and diluted net loss per share for those periods are identical. Holders of Series E convertible preferred stock met the definition of participating securities, which required the Company to apply the two-class method to compute both basic and diluted earnings (loss) per share. The two-class method is an earnings allocation formula that treats participating securities as having rights to earnings that would otherwise have been available to common stockholders. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all earnings for the period had been distributed. In the event the Board of Directors declared dividends or any distributions, the available distributions would be distributed (i) first, to the Series E convertible preferred stock until such holders have received on a cumulative basis an amount per share equal to the Series E original issue price, and (ii) second, to the holders of common stock and Series E convertible preferred stock (on an as converted basis) on a pro rata, pari passu, basis. The attribution of earnings to the Series E convertible preferred stockholders was based on its contractual rights to receive dividends and, for the quarter in which they converted, the attribution was calculated using a weighted-average method. The Series E convertible preferred stock did not contractually participate in the Company’s net losses, and therefore undistributed losses were not allocated to Series E convertible preferred stock. Immediately prior to the completion of the Company’s IPO on September 22, 2021, all outstanding shares of the Series E convertible preferred stock automatically converted on a one-to-one basis into an aggregate of 27,011,500 shares of common stock. See Note 12 for additional information related to the Series E convertible preferred stock. The dilutive effect of stock options, warrants and unvested nonparticipating restricted stock is based on the treasury stock method while the dilutive effect of the convertible preferred stock is based on the if-converted method. These potential common stock equivalents are only included in the calculations when their effect is dilutive. The Company presents the more dilutive of the two-class method or if-converted method as diluted net income (loss) per share during the period. For the three and six months ended June 30, 2021, the Company presented diluted net income per share under the two-class method. The following table presents information necessary to calculate earnings (loss) per share: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income (loss) attributable to Thorne HealthTech, Inc. $ ( 5,590,705 ) $ ( 88,230 ) $ ( 611,646 ) $ 4,618,260 Undistributed earnings (loss) attributable to Series E convertible preferred stockholders — ( 88,230 ) — 4,618,260 Numerator for basic earnings (loss) per share—net income (loss) available to Thorne HealthTech, Inc. common stockholders (A) ( 5,590,705 ) — ( 611,646 ) — Effect of dilutive securities: Undistributed earnings (loss) attributable to Series E convertible preferred stockholders—basic — ( 88,230 ) — 4,618,260 Undistributed earnings (loss) attributable to Series E convertible preferred stockholders—diluted — 88,230 — ( 4,618,260 ) Numerator for diluted earnings (loss) per share—net income (loss) available to Thorne HealthTech, Inc. common stockholders (C) ( 5,590,705 ) — ( 611,646 ) — Denominator (1) : Denominator for basic earnings (loss) per share—weighted average shares (B) 52,731,604 17,650,035 52,648,653 17,650,035 Denominator for diluted earnings (loss) per share—adjusted weighted average common stock and common stock equivalents (D) 52,731,604 17,650,035 52,648,653 17,650,035 Basic earnings (loss) per share (A/B) $ ( 0.11 ) $ — $ ( 0.01 ) $ — Diluted earnings (loss) per share (C/D) $ ( 0.11 ) $ — $ ( 0.01 ) $ — (1) For the three and six months ended June 30, 2022, 18.1 million and 17.2 million warrants and stock-based awards, respectively, were excluded from the computation of diluted earnings (loss) per share because the effect would have been anti-dilutive under the treasury stock method .

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Royalties and Other Agreements - The Company has entered into various agreements that require future payments. The agreements call for future payments to a major hospital for use of their trademarks and tradenames in advertising the benefits of supplements and provides the Company access to research information owned by the hospital and provides for the hospital to perform clinical trials and to support the Company’s products. As of June 30, 2022, future annual minimum commitments under these agreements are as follows: Remainder of 2022 $ 415,000 2023 562,500 Total $ 977,500 The Company also has various royalty agreements, that are dependent on future sales. Total royalties paid during the three and six months ended June 30, 2022 w ere $ 0.1 million and $ 0.2 million, respectively ( three and six months ended June 30, 2021— $ 0.2 million). Other - In 2017, the Company received incentives totaling $ 0.8 million from Berkeley County, South Carolina, which includes certain performance obligations that must be met over the next seven years and maintained by the company for five years once attained. The grant agreement includes the potential for repayment of proceeds in whole or in part for failure to satisfy the performance obligations. As of June 30, 2022, the Company has satisfied the requirements and Berkeley County has not asked for repayment of these proceeds. Contingencies The Company, like other manufacturers of products that are ingested, faces an inherent risk of exposure to product liability claims if, among other things, the use of its product results in personal injury. The Company maintains product liability insurance to manage these risks. However, there can be no assurance the amount of insurance would be sufficient to cover all product liability claims. In addition to the matter discussed below, occasionally the Company is involved in lawsuits arising in the ordinary course of its operations. The Company’s management does not expect the ultimate resolution of pending legal actions to have a material effect on the consolidated financial statements of the Company. The Company is aware of two U.S. patents with claims relating to compositions of Nicotinamide Riboside – an ingredient contained in several of the Company’s nutritional supplement products. The two patents were issued to the Trustees of Dartmouth College and licensed to ChromaDex Corporation (ChromaDex), of Los Angeles, California. On December 1, 2020, and February 1, 2021, the Company filed separate petitions for inter partes review against the two patents - U.S. Patent No. 8,383,086 and U.S. Patent No. 8,197,807 at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office seeking to invalidate the two patents. On June 10, 2021, the Patent Trial and Appeal Board issued a decision granting institution of inter partes review against U.S. Patent No. 8,383,086, and on August 12, 2021, the Patent Trial and Appeal Board issued a decision granting institution of inter partes review against U.S. Patent No. 8,197,807. On May 31, 2022, the Patent Trial and Appeal Board issued a decision in which it invalidated the challenged claim in U.S. Patent No. 8,838,086. On August 2, 2022, the patent owner filed a “Patent Owner Notice of Appeal” with the U.S. Court of Appeals for the Federal Circuit. The Patent Trial and Appeal Board is expected to render a decision regarding U.S. Patent No. 8,197,807 in mid-August 2022. On May 12, 2021, the Trustees of Dartmouth College and ChromaDex filed a complaint against the Company in the U.S. District Court for the Southern District of New York, alleging the Company’s infringement of U.S. Patent Nos. 8,383,086 and 8,197,807. The complaint seeks to enjoin the Company from selling nutritional supplement products that contain Nicotinamide Riboside and further seeks monetary damages for alleged infringement of the patents. On August 20, 2021, the trial judge in the patent infringement litigation issued an Order to Stay the litigation during the pendency of the two inter partes reviews. On September 21, 2021, the U.S. District Court for the District of Delaware issued a summary judgment holding that U.S. Patent Nos. 8,383,086 and 8,197,807 are invalid in ChromaDex, Inc. and Trustees of Dartmouth College v. Elysium Health, Inc. The Company has not recorded a loss in connection with this matter because the Company believes that a loss is currently neither probable nor estimable.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). These condensed consolidated financial statements include the operations of the Company and all of its wholly-owned subsidiaries, as well as majority-owned subsidiaries over which the Company exercises control and, when applicable, entities for which the Company has a controlling financial interest or variable interest for which the Company is the primary beneficiary. All significant intercompany accounts and transactions have been eliminated in consolidation. On September 10, 2021, the Company approved and effected a 445 -for-1 forward stock split of the Company’s Class A common stock, Class B common stock and Series E convertible preferred stock. The par value and other terms of the common stock and preferred stock were not affected by the stock split. All related share and per share amounts have been retroactively adjusted in these condensed consolidated financial statements for all periods presented to reflect the 445 -for-1 forward stock split. Furthermore, other related information, including shares of common stock underlying the Company’s warrants, stock options and restricted stock units and their respective exercise prices have been retroactively adjusted in these condensed consolidated financial statements for all periods presented to reflect the 445 -for-1 forward stock split.
Unaudited Consolidated Financial Statements	Unaudited Condensed Consolidated Financial Statements The condensed consolidated balance sheet as of June 30, 2022, the condensed consolidated statements of operations, condensed consolidated statements of comprehensive income (loss) and the condensed consolidated statements of convertible preferred stock and stockholders’ equity (deficit) for the three and six months ended June 30, 2022 and 2021 and the condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021, are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair statement of the Company’s financial position as of June 30, 2022 and the results of operations and cash flows for the periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three and six months ended June 30, 2022 and 2021, are also unaudited. The condensed consolidated results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of results to be expected for the year ending December 31, 2022, nor for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2021, included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2021 , included in the Company’s Annual Report on Form 10-K filed on March 16, 2022.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. The Company bases its estimates on its historical experience and on assumptions that the Company believes are reasonable; however, actual results could significantly differ from those estimates. There have been no significant changes from the significant accounting policies disclosed in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2021 .
Concentrations of Risk	Concentrations of Risk Credit Risk - Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash and accounts receivable. Although the Company places its cash and cash equivalents with high quality institutions, these balances can exceed federally insured limits. Concentrations of credit risk primarily relate to unsecured trade receivables. Major customers who accounted for more than 10 % of the Company’s total net receivables were as follows: June 30, December 31, 2022 2021 Emerson Ecologics, LLC 26.1 % 33.3 % Pattern Inc. 18.5 % * iHerb, Inc. 12.1 % 41.3 % * Represents less than 10% Sales - Major customers who accounted for more than 10 % of the Company’s total net sales were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Pattern Inc. 36.7 % 25.1 % 34.2 % 28.3 % Emerson Ecologics, LLC * 12.5 % * 12.3 % iHerb, Inc. * 17.5 % * 15.3 % * Represents less than 10%
In-process Research & Development	In-process Research and Development In-process research and development (IPR&D) was recorded at its fair value using a discounted cash flow model and was assigned to acquired research and development assets that were not fully developed as of the completion of the acquisition of Drawbridge Health, Inc. (the Drawbridge Transaction; see Note 4). IPR&D acquired in an asset purchase is capitalized on the Company’s condensed consolidated balance sheets at its acquisition-date fair value if the acquired IPR&D has alternative future use. For the IPR&D acquired from the Drawbridge Transaction it was determined that the IPR&D had no alternative future use, and therefore it was expensed immediately following the Drawbridge Transaction. Fair value measurement was classified as Level 3 under the fair value hierarchy.
Fair Value Measurements	Fair Value Measurements Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: • Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date. • Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or that can be corroborated by observable market data. • Level 3: Significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. The carrying amounts of certain financial instruments, which include cash and cash equivalents, receivables, accounts payable and accrued expenses approximate their fair values as of June 30, 2022 and December 31, 2021 due to their short-term nature and management’s belief that their carrying amounts approximate the amount for which the assets could be sold or the liabilities could be settled.
Deferred Offering Costs	Deferred Offering Costs The Company capitalizes within other assets, certain legal, accounting and other third-party fees directly related to the Company’s in-process equity financings until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds received as a result of the offering. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written off to operating expenses. On September 22, 2021, the Company’s Registration Statement on Form S-1, as amended, was declared effective and on September 23, 2021, the Company’s common stock began trading on the Nasdaq Global Select Market, under the ticker symbol “THRN”. On September 27, 2021, the Company closed its initial public offering (IPO) of 7,000,000 shares of common stock. Through the completion of the offering, the Company incurred $ 10.0 million of offering costs, which had been capitalized prior to the completion of the offering. Upon closing of the offering, the Company reclassified these amounts to additional paid-in capital, as a reduction of the offering proceeds.
Revenue Recognition	Revenue Recognition The Company accounts for revenues under Financial Accounting Standards Board (FASB) Topic 606, Revenue from Contracts with Customers (ASC 606) using the following steps: • identify the contract, or contracts, with a customer; • identify the performance obligations in the contract; • determine the transaction price; • allocate the transaction price to the identified performance obligations; and • recognize revenue when, or as, the Company satisfies the performance obligations. The Company recognizes revenue at a point in time when it satisfies a performance obligation by transferring control over a product and other promised goods and services to a customer. Significant judgments made in the application of ASC 606 include determining the transaction price and the timing of transfer of control of the performance obligation (i.e., sale of product). The Company considers several factors in determining the point in time when control transfers to the customer. These factors include that legal title transfers to the customer, the Company has a present right to payment and the customer has assumed the risks and rewards of ownership. Professional/Business-to-Business (B2B) Sales: The Company sells to wholesale customers, including healthcare professionals, retail stores and through various online sites operated by authorized resellers. Certain customers resell Company products in online marketplaces, however, no inventories are held on consignment; revenue is recognized when control of the goods is transferred to these customers which is at the time of shipment. The terms of payment over the recognized receivables from distributors are less than one year, and therefore these sales do not have any significant financing components. The Company uses standard price lists in determining the transaction price, adjusted for estimates of variable consideration. Any discounts stated or implied are allocated entirely to the sole performance obligation. Direct-to-Consumer (DTC) Transaction Sales: The Company also sells direct to consumers online through a Company owned and operated website. Revenue from online sales is recognized at time of shipment of the product. In addition, the Company sells testing services and test kits. Testing services and test kits are recorded as revenue when the test results are provided to the customer. Shipping and handling costs are considered a fulfillment activity and are expensed as incurred. DTC Subscription Sales: The Company offers its customers the ability to opt into recurring automatic refills on Thorne.com and Amazon.com. Revenue is recognized under the subscription program when product is shipped to the consumer. No funds are collected at the time a consumer signs up for a subscription and the customer can cancel or modify a subscription at any time at no cost to the customer. On the Thorne.com website, customers are allowed to subscribe at a frequency of monthly, every 45 days , every 2 months , every 3 months , or every 4 months . For all these frequencies, a 10 % discount is offered on retail refill orders. For orders placed through Amazon.com, the discount ranges from 5 % to 10 % depending on the number of products to which a customer is subscribed; the average discount on Amazon for the Company’s subscriptions is approximately 6 %. The Company records revenues, net of estimated discounts. If a customer is not satisfied for any reason with a product purchased, the customer can return it to the place of purchase to receive a refund, credit, or a replacement product. The return or refund request must be submitted within 60 days of the date of purchase. The Company estimates returns and accrues for potential returns based on historical data. There are no material differences in the Company’s revenue recognition policy between the DTC subscription program and the DTC transaction program. The Company primarily sells to customers in the United States, but also sells in international markets. Regardless of customer location, customers are invoiced and payments are required to be made in U.S. dollars. The Company has elected to exclude sales and use taxes for non-exempt customers from the transaction price and, therefore, sales and use taxes are excluded from revenue.
Product Returns, Sales Incentives and Other Forms of Variable Consideration	Product Returns, Sales Incentives and Other Forms of Variable Consideration In measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Such elements of variable consideration include product return rights, discounts, rebates, volume discounts and rebates, promotional offers and other marketing offers that may impact net sales. For the sale of goods with a right of return, the Company only recognizes revenue for the consideration it expects to be entitled to (considering the products to be returned) and records a sales return accrual within accrued expenses for the amount it expects to credit back its customers. Given that most product returns cannot be resold to another customer, the Company does not recognize an asset in inventory, or a corresponding adjustment to cost of sales, for the right to recover goods from customers associated with the estimated returns. The sales return accrual includes estimates that directly impact reported net sales. These estimates are calculated based on a history of actual returns and estimated future returns. In addition, as necessary, sales return accruals may be established for significant future known or anticipated events. The types of future known or anticipated events that are considered and will continue to be considered, include the Company’s decision to continue to support new and existing products. Returns are handled on a case-by-case basis, but generally returns are accepted when the customer is unsatisfied with the product. The Company has accrued an estimate for returns related to a future period. Sales returns accrued as of June 30, 2022 and December 31, 2021, were approxima tely $ 0.1 million and recorded as a reduction to net sales within the condensed consolidated statements of operations. The Company estimates sales incentives and other variable consideration using the expected value method. The variable consideration is included in the transaction price only to the extent that it is probable, in the Company's judgment, that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Under this method, certain forms of variable consideration are based on volumes of sales to the customer, which requires subjective estimates. These estimates are supported by historical results, as well as specific facts and circumstances related to the current period. A select few customers, because of their size, are offered a discount for early payment. The Company also enters into transactions and makes payments to certain of its customers related to advertising, some of which involve cooperative relationships with customers. These activities can be arranged either with unrelated third parties or in conjunction with the customer. To the extent the Company receives a distinct good or service in exchange for consideration and the fair value of the benefit can be reasonably estimated, the Company’s share of the costs of these transactions (regardless of to whom they were paid) are reflected in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations. The Company also enters into other advertising activities arranged with customers. Since these activities cannot be arranged with unrelated third parties and no distinct good or service is received in exchange for consideration, the fair value of the benefit is not reasonably estimated. The Company’s share of the costs for these transactions paid to customers are reflected as a reduction in the transaction price within net sales in the accompanying condensed consolidated statements of operations. For certain sales, the Company incurs incremental costs of obtaining the contract in the form of sales commissions. The sales commissions incurred are short-term (less than 12 months in duration) and directly correlated to the sales generated, and therefore are expensed as incurred. The following table presents disaggregated revenues by geography, as determined by the country products were shipped to: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amount Percentage Amount Percentage Amount Percentage Amount Percentage Domestic $ 52,542,648 93.7 % $ 40,845,805 95.2 % $ 105,058,997 94.9 % $ 82,725,091 94.7 % Foreign 3,525,178 6.3 % 2,044,160 4.8 % 5,677,027 5.1 % 4,648,614 5.3 % Net sales $ 56,067,826 100.0 % $ 42,889,965 100.0 % $ 110,736,024 100.0 % $ 87,373,705 100.0 % The following table presents disaggregated revenues based on sales channel: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amount Percentage Amount Percentage Amount Percentage Amount Percentage DTC subscription sales $ 9,667,533 17.2 % $ 5,546,028 12.9 % $ 18,015,429 16.3 % $ 11,026,552 12.6 % DTC transaction sales 19,214,981 34.3 % 11,486,170 26.8 % 36,677,282 33.1 % 25,409,646 29.1 % Professional/B2B 27,185,312 48.5 % 25,857,767 60.3 % 56,043,313 50.6 % 50,937,507 58.3 % Net sales $ 56,067,826 100.0 % $ 42,889,965 100.0 % $ 110,736,024 100.0 % $ 87,373,705 100.0 %
Segments	Segments The Company operates in one reportable segment: the selling of innovative solutions and personalized approaches to health and wellness. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately and the allocation of resources and assessment of performance are based on the Company’s condensed consolidated operating results and where the best future opportunities arise.
Recent Accounting Pronouncements – Adopted	Recent Accounting Pronouncements – Adopted Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . In August 2020, the FASB issued this ASU to simplify the accounting for convertible instruments. This ASU also requires entities to use the if-converted method for all convertible instruments in calculating diluted earnings-per-share. This update was adopted by the Company effective January 1, 2022. The adoption did not have a material impact on its condensed consolidated financial statements. ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the Emerging Issues Task Force . In May 2021, the FASB issued this ASU to provide explicit guidance on accounting by issuers for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after the modification or exchange. This update was adopted by the Company effective January 1, 2022. The adoption did not have a material impact on its condensed consolidated financial statements.
Recent Accounting Pronouncements – Not Yet Adopted	Recent Accounting Pronouncements – Not Yet Adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . In June 2016, the FASB issued this ASU to amend the current accounting guidance which requires the measurement of all expected losses to be based on historical experience, current conditions and reasonable and supportable forecasts. For trade receivables, loans and other financial instruments, the Company will be required to use a forward-looking expected loss model that reflects probable losses rather than the incurred loss model for recognizing credit losses. This ASU was amended by ASU 2019-10 to be effective for smaller reporting companies for fiscal years beginning after December 15, 2022. The Company does not believe the adoption of this ASU will have a material impact on its consolidated financial statements and related disclosures. ASU 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting . In March 2020, the FASB issued guidance providing optional expedients and exceptions to account for the effects of reference rate reform to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued. The optional guidance, which became effective on March 12, 2020 and can be applied through December 31, 2022, has not impacted the Company’s consolidated financial statements. The Company has no contracts that reference LIBOR and does not believe the adoption of this ASU will have a material impact on its consolidated financial statements and related disclosures. ASU 2021-08, Business Combinations – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . In October 2021, the FASB issued guidance intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 as if they had originated the contracts, as opposed to fair value on the date of acquisition. The standard will be effective for business combinations occurring after January 1, 2023. Early adoption is permitted. The Company is currently evaluating the impact that this guidance may have on its consolidated financial statements and related disclosures.
COVID-19 Pandemic	COVID-19 Pandemic and CARES Act The full impact of the COVID-19 outbreak continues to evolve. As such, the impact of this pandemic on the Company’s financial condition is uncertain. Management is actively monitoring the impact of this virus on its financial condition, liquidity, operations, suppliers, customers and workforce. The Company's unaudited condensed consolidated financial statements presented herein reflect the latest estimates and assumptions made by management that affect the reported amounts of assets and liabilities and related disclosures as of the date of the condensed consolidated financial statements and reported amounts of revenue and expenses during the reporting periods presented. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act, was enacted. The CARES Act includes provisions relating to refundable payroll tax credits, deferment of employer-side Social Security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions and technical corrections to tax depreciation methods for qualified improvement property. The Company deferred the employer portion of payroll taxes during the year ended December 31, 2020, totaling approximately $ 1.0 million. During the year ended December 31, 2021, the Company paid $ 0.5 million of the deferred payroll taxes. As of June 30, 2022 the remaining deferred payroll taxes of $ 0.5 million will be payable by December 31, 2022 .

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Concentration of Risk	Major customers who accounted for more than 10 % of the Company’s total net receivables were as follows: June 30, December 31, 2022 2021 Emerson Ecologics, LLC 26.1 % 33.3 % Pattern Inc. 18.5 % * iHerb, Inc. 12.1 % 41.3 % * Represents less than 10% Sales - Major customers who accounted for more than 10 % of the Company’s total net sales were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Pattern Inc. 36.7 % 25.1 % 34.2 % 28.3 % Emerson Ecologics, LLC * 12.5 % * 12.3 % iHerb, Inc. * 17.5 % * 15.3 % * Represents less than 10%
Summary of Revenue Disaggregated by Geography	The following table presents disaggregated revenues by geography, as determined by the country products were shipped to: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amount Percentage Amount Percentage Amount Percentage Amount Percentage Domestic $ 52,542,648 93.7 % $ 40,845,805 95.2 % $ 105,058,997 94.9 % $ 82,725,091 94.7 % Foreign 3,525,178 6.3 % 2,044,160 4.8 % 5,677,027 5.1 % 4,648,614 5.3 % Net sales $ 56,067,826 100.0 % $ 42,889,965 100.0 % $ 110,736,024 100.0 % $ 87,373,705 100.0 %
Summary of Revenues Based Upon Sales Channel	The following table presents disaggregated revenues based on sales channel: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amount Percentage Amount Percentage Amount Percentage Amount Percentage DTC subscription sales $ 9,667,533 17.2 % $ 5,546,028 12.9 % $ 18,015,429 16.3 % $ 11,026,552 12.6 % DTC transaction sales 19,214,981 34.3 % 11,486,170 26.8 % 36,677,282 33.1 % 25,409,646 29.1 % Professional/B2B 27,185,312 48.5 % 25,857,767 60.3 % 56,043,313 50.6 % 50,937,507 58.3 % Net sales $ 56,067,826 100.0 % $ 42,889,965 100.0 % $ 110,736,024 100.0 % $ 87,373,705 100.0 %

Mergers and Acquisitions (Table

Mergers and Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2022
Drawbridge Health Inc
Asset Acquisition [Line Items]
Summary of the Assets and Liabilities Acquired	The assets and liabilities acquired based on their fair value were as follows: Cash $ 11,823 Accounts receivable 8,686 Prepaid expenses and other current assets 711,389 Inventories 10,051 Property and equipment 914,716 Operating lease right-of-use assets 410,732 Intangible asset consisting of in process research and development 1,563,015 Other assets 22,782 Accounts payable ( 701,242 ) Other accrued expenses ( 864,483 ) Current portion of operating lease liabilities ( 263,509 ) Long term operating lease, net of current portion ( 147,223 ) Net assets acquired $ 1,676,737 Less: non-controlling interest ( 209,592 ) Net assets acquired by Thorne HealthTech, Inc. $ 1,467,145
Nutrativa LLC Acquisition
Asset Acquisition [Line Items]
Schedule of Recognized Identifiable Tangible and Intangible Assets Acquired and Liabilities assume	The following table sets forth the preliminary allocation of the purchase price to Nutrativa’s identifiable tangible and intangible assets acquired and liabilities assumed, including measurement period adjustments: Cash $ 17,713 Accounts receivable, net 14,740 Inventories, net 274 Property and equipment, net 3,256,996 Intangible assets, net 10,200,000 Goodwill 2,100,358 Accounts payable ( 181,913 ) Other accrued expenses ( 203 ) Net assets acquired $ 15,407,965

Consolidated Variable Interes_2

Consolidated Variable Interest Entities (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Variable Interest Entities	Summary information for Thorne Asia JV, excluding intercompany activity with the Company, is included in the condensed consolidated balance sheets for the periods presented is as follows: June 30, 2022 Total assets $ 4,636,316 Less: Total liabilities 31,394 Net assets (liabilities) $ 4,604,922 The results of operations for Thorne Asia JV, excluding intercompany activity with the Company, included in the condensed consolidated statements of operations for the periods presented is as follows: Three Months Ended Six Months Ended June 30, 2022 Net sales $ 10,599 $ 16,491 Net loss ( 175,482 ) ( 546,793 ) Net loss — non-controlling interest ( 85,986 ) ( 267,929 ) Net loss attributable to Thorne HealthTech, Inc. $ ( 89,496 ) $ ( 278,864 )

Inventories, Net (Tables)

Inventories, Net (Tables)	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories, net are as follows: June 30, December 31, 2022 2021 Raw materials $ 33,839,020 $ 22,620,773 Work in process 165,870 422,196 Finished goods 27,068,958 18,413,853 Reserve for slow moving and obsolete inventory ( 602,380 ) ( 444,698 ) Inventories, net $ 60,471,468 $ 41,012,124

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Components of Property and Equipment	Property and equipment, net are as follows: June 30, December 31, 2022 2021 Machinery and equipment $ 13,914,862 $ 9,937,510 Furniture and fixtures 509,054 491,173 Office equipment 777,215 1,111,141 Leasehold improvements 19,565,760 19,431,916 Vehicles 98,282 98,282 Lab equipment 2,938,346 2,930,059 Purchased software 2,150,051 2,107,327 Internally-developed software 425,611 — Total property and equipment 40,379,181 36,107,408 Less accumulated depreciation and amortization ( 12,373,904 ) ( 11,262,651 ) In-process assets, including deposits on new equipment 2,759,129 2,185,643 Property and equipment, net $ 30,764,406 $ 27,030,400

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of carrying amount of goodwill	The following table sets forth the change in the carrying amount of goodwill during the six months ended June 30, 2022: Balance as of December 31, 2021 $ 14,440,683 Acquisitions 2,100,358 Balance as of June 30, 2022 $ 16,541,041
Schedule of Finite - Lived Intangible Assets	Finite-lived intangible assets are as follows: June 30, 2022 Gross Carrying Value Accumulated Amortization Net Customer relationships $ 6,500,000 $ ( 3,900,000 ) $ 2,600,000 Trade names 7,600,000 ( 6,080,000 ) 1,520,000 Existing technology/reformulations 12,400,000 ( 1,972,500 ) 10,427,500 License agreements 2,754,002 ( 1,212,094 ) 1,541,908 $ 29,254,002 $ ( 13,164,594 ) $ 16,089,408 December 31, 2021 Gross Carrying Value Accumulated Amortization Net Customer relationships $ 6,500,000 $ ( 3,737,500 ) $ 2,762,500 Trade names 8,640,000 ( 6,866,667 ) 1,773,333 Existing technology/reformulations 3,207,923 ( 2,694,590 ) 513,333 Research and development formulas 800,000 ( 800,000 ) — License agreements 8,591,822 ( 7,048,672 ) 1,543,150 $ 27,739,745 $ ( 21,147,429 ) $ 6,592,316
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Future estimated amortization expense of the Company’s intangible assets as of June 30, 2022 is as follows: Remainder of 2022 $ 1,306,033 2023 2,391,234 2024 2,080,817 2025 1,551,026 2026 1,208,734 Thereafter 7,551,564 Total $ 16,089,408

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt balances and associated interest rates and maturities are as follows: June 30, December 31, Note payable with quarterly principal and interest payments of $ 8,250 per quarter, with fixed interest of 5.44 % and maturity September 10, 2026 $ 374,888 $ 413,574 Note payable with quarterly principal and interest payments of $ 56,548 per quarter, with fixed interest of 4.89 % and maturity March 20, 2025 578,686 675,836 Note payable with quarterly principal and interest payments of $ 30,917 per quarter, with fixed interest of 6.94 % and maturity August 12, 2024 233,908 286,255 Note payable with quarterly principal and interest payments of $ 30,917 per quarter, with fixed interest of 6.94 % and maturity July 15, 2023 146,850 202,142 1,334,332 1,577,807 Less: Current portion of long-term debt ( 508,844 ) ( 494,173 ) Long-term debt, net of current portion $ 825,488 $ 1,083,634

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Summary of Operating and Finance Leases	The balances for the operating and finance leases where the Company is the lessee are presented as follows within the condensed consolidated balance sheets: June 30, December 31, Operating lease: Operating lease right-of-use assets, net $ 16,203,487 $ 17,836,756 Current portion of operating lease liabilities 1,599,190 2,633,236 Operating lease liabilities, net of current portion 27,026,923 27,605,739 Total operating lease liabilities $ 28,626,113 $ 30,238,975 Finance lease: Finance lease right-of-use assets $ 716,402 $ 883,076 Current portion of finance lease liabilities 391,003 413,487 Finance lease liabilities, net of current portion 348,352 482,544 Total finance lease liabilities $ 739,355 $ 896,031
Summary of Lease Expense	The components of lease expense are as follows within the condensed consolidated statements of operations: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Operating lease expense: Operating lease cost (1) $ 1,461,356 $ 1,369,459 $ 2,922,711 $ 2,602,167 Finance lease expense: Amortization of leased assets 107,112 94,418 219,512 168,333 Interest on lease liabilities 10,459 13,748 22,047 25,048 Total lease expense $ 1,578,927 $ 1,477,625 $ 3,164,270 $ 2,795,548 (1) Includes short-term leases and variable lease costs, which are immaterial.
Schedule of Lease Terms and Discount Rate	The weighted-average remaining lease term and weighted-average discount rate as of June 30, 2022 and December 31, 2021, were as follows: June 30, December 31, Weighted average remaining lease term (years) Operating leases 13.93 years 13.73 years Finance leases 2.01 years 2.33 years Weighted average discount rate applied Operating leases 8.9 % 9.2 % Finance leases 5.9 % 6.1 %
Summary of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases where the Company is the lessee is as follows: Six Months Ended June 30, 2022 2021 Operating cash outflows from operating leases $ 2,902,305 $ 3,244,257 Operating cash outflows from finance leases (interest payments) $ 22,047 $ 25,048 Financing cash outflows from finance leases $ 209,514 $ 171,734 Leased assets obtained in exchange for finance lease liabilities $ 52,838 $ 420,361 Leased assets obtained in exchange for operating lease liabilities $ — $ 2,913,002
Summary of Maturities of Operating and Finance Lease Liabilities	As of June 30, 2022, the maturities of the operating and finance lease liabilities are as follows: Operating Leases Finance Leases Remainder of 2022 $ 2,218,628 $ 233,900 2023 3,497,422 343,422 2024 3,589,920 157,455 2025 3,559,583 22,189 2026 3,325,639 38,944 Thereafter 35,705,779 — Total lease payments $ 51,896,971 $ 795,910 Less: imputed interest 23,270,858 56,555 Total present value of lease liabilities $ 28,626,113 $ 739,355 Less: current portion of lease liabilities 1,599,190 391,003 Long-term portion of lease liabilities $ 27,026,923 $ 348,352

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Schedule of Fair Value Measurement Inputs and Valuation Techniques	The Black-Scholes model was used to value the liability-classified warrants. The following assumptions were used: June 30, December 31, 2022 2021 Fair market value $ 4.84 $ 6.21 Exercise Price $ 6.74 $ 6.74 Term (years) 8.0 8.5 Volatility 75 % 75 % Annual dividend — — Risk-free interest rate 3.01 % 1.48 %
Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The fair value of financial instruments measured on a recurring basis is as follows: June 30, 2022 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 1,529,586 — 1,529,586 $ — December 31, 2021 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 2,058,566 — — $ 2,058,566
Summary Of Change in Fair value, as Determined by Level 3 inputs, for all Assets and Liabilities	Changes in the ability to observe valuation inputs may result in a reclassification of levels within the fair value hierarchy. The following table summarizes the changes in Level 3 measurement and transfers in or out of the Level 3 fair value hierarchy, for the warrant liability, during the six months ended June 30, 2022: Warrant Balance as of December 31, 2021 $ 2,058,566 Change in fair value during the three months ended March 31, 2022 65,919 Transfer to level two during the three months ended June 30, 2022 ( 2,124,485 ) Balance as of June 30, 2022 $ —

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock-based compensation expense	Stock-based compensation expense for the periods indicated is as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Stock options $ 237,786 $ 24,143 $ 475,572 $ 534,665 Restricted stock units 2,904,050 — 4,675,676 — Total stock-based compensation expense $ 3,141,836 $ 24,143 $ 5,151,248 $ 534,665
Schedule of Stock Option Activity	The following table summarizes stock option activity for the six months ended June 30, 2022: Options Outstanding Weighted- Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic (1) Outstanding as of January 1, 2022 9,699,656 $ 5.28 6.22 $ 12.3 Granted — - Exercised ( 179,055 ) 1.36 Cancelled/forfeited — - Outstanding as of June 30, 2022 9,520,601 5.35 5.58 3.6 Vested and expected to vest as of June 30, 2022 9,520,601 $ 5.35 5.58 $ 3.6 Exercisable as of June 30, 2022 1,690,381 $ 2.71 2.42 $ 3.6 (1) Aggregate intrinsic value is presented in millions of U.S. dollars and represents the difference between the closing fair value of the underlying common stock and the exercise price of outstanding, in-the-money options on the date of measurement.
Schedule Of Stock Options Outstanding	The following table summarizes additional information related to stock options for the periods presented: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Weighted-average grant date fair value of stock options granted (1) N/A N/A N/A N/A Grant date fair value of stock options vested (1)(2) N/A N/A N/A N/A Intrinsic value of stock options exercised (3) $ 8,133 N/A $ 857,460 N/A (1) The three and six months ended June 30, 2021 excludes 1,959,335 stock options issued in exchange for outstanding stock options of Onegevity, in connection with the merger. The stock option exchange was determined to be materially a “like-for-like” transaction and there was no incremental stock compensation expense recorded by the Company. The Company compared the fair value of the stock options immediately before and after the exchange and determined that the exchange did not result in incremental compensation expense. (2) During the three and six months ended June 30, 2022 and 2021, there were no stock options that vested. (3) Shares of the Company’s common stock, traded under the symbol “THRN,” have been publicly traded since September 23, 2021, when the Company’s common stock was listed and began trading on the Nasdaq Global Select Market (the “Nasdaq”). No market for the Company’s stock existed prior to September 23, 2021. There were no stock option exercises prior to the IPO date.
Schedule of Non Vested Restricted Stock Shares Activity	The following table summarizes RSU activity for the six months ended June 30, 2022: Number Weighted- Outstanding as of January 1, 2022 3,406,760 $ 9.82 Granted 2,217,248 6.91 Released — — Cancelled/forfeited ( 5,000 ) 8.40 Outstanding as of June 30, 2022 5,619,008 $ 8.67 Vested and expected to vest as of June 30, 2022 5,619,008 $ 8.67
Schedule of RSUs	The following table summarizes additional information related to RSUs for the periods presented: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Weighted-average grant date fair value of RSUs granted (1) $ 6.91 N/A $ 6.91 N/A Grant date fair value of RSUs vested (1)(2) N/A N/A N/A N/A Intrinsic value of RSUs released (1)(2) N/A N/A N/A N/A (1) The three and six months ended June 30, 2021 excludes 472,590 R SUs issued in exchange for outstanding profits interest units held by employees of Onegevity, in connection with the merger. The RSU exchange was determined to be materially a “like-for-like” transaction and there was no incremental stock compensation expense recorded by the Company. The Company compared the fair value of the RSUs immediately before and after the exchange and determined that the exchange did not result in incremental compensation expense. (2) During the three and six months ended June 30, 2022 and 2021, there were no RSUs that vested or released.

Basic and Diluted Earnings (Los

Basic and Diluted Earnings (Loss) per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Basic and Diluted Earnings (Loss) per Share	The following table presents information necessary to calculate earnings (loss) per share: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income (loss) attributable to Thorne HealthTech, Inc. $ ( 5,590,705 ) $ ( 88,230 ) $ ( 611,646 ) $ 4,618,260 Undistributed earnings (loss) attributable to Series E convertible preferred stockholders — ( 88,230 ) — 4,618,260 Numerator for basic earnings (loss) per share—net income (loss) available to Thorne HealthTech, Inc. common stockholders (A) ( 5,590,705 ) — ( 611,646 ) — Effect of dilutive securities: Undistributed earnings (loss) attributable to Series E convertible preferred stockholders—basic — ( 88,230 ) — 4,618,260 Undistributed earnings (loss) attributable to Series E convertible preferred stockholders—diluted — 88,230 — ( 4,618,260 ) Numerator for diluted earnings (loss) per share—net income (loss) available to Thorne HealthTech, Inc. common stockholders (C) ( 5,590,705 ) — ( 611,646 ) — Denominator (1) : Denominator for basic earnings (loss) per share—weighted average shares (B) 52,731,604 17,650,035 52,648,653 17,650,035 Denominator for diluted earnings (loss) per share—adjusted weighted average common stock and common stock equivalents (D) 52,731,604 17,650,035 52,648,653 17,650,035 Basic earnings (loss) per share (A/B) $ ( 0.11 ) $ — $ ( 0.01 ) $ — Diluted earnings (loss) per share (C/D) $ ( 0.11 ) $ — $ ( 0.01 ) $ — (1) For the three and six months ended June 30, 2022, 18.1 million and 17.2 million warrants and stock-based awards, respectively, were excluded from the computation of diluted earnings (loss) per share because the effect would have been anti-dilutive under the treasury stock method .

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Annual Minimum Commitments	As of June 30, 2022, future annual minimum commitments under these agreements are as follows: Remainder of 2022 $ 415,000 2023 562,500 Total $ 977,500

Description of Business and N_2

Description of Business and Nature of Operations - Additional Information (Detail)	Jun. 17, 2010
Thorne Research Inc [Member]
Business combination, Percentage of voting interest acquired	100%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)			6 Months Ended	12 Months Ended
	Sep. 27, 2021 USD ($) shares	Sep. 10, 2021	Jun. 30, 2022 USD ($) Number	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Stock split, Conversion ratio		445
Offering costs, Capitalized	$ 10,000,000
Revenue, Performance obligation, Subcription timing allowed to customer			45 days
Accrued sales returns, Current			$ 100,000	$ 100,000
Number of reportable segment | Number			1
Stock Issued During Period, Shares, New Issues | shares	7,000,000
Coronavirus Aid Relief And Economic Security Cares Act [Member]
Deferred payroll taxes, Accrued			$ 500,000
Deferred payroll taxes, Paid					$ 1,000,000
Deferred payroll taxes, Paid				$ 500,000
Deferred Payroll Taxes Payable, Date			Dec. 31, 2022
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Minimum [Member]
Concentration risk percentage			10%
Total Sales [Member] | Customer Concentration Risk [Member] | Minimum [Member]
Concentration risk percentage			10%
Sales Channel Professional Business To Business Sales [Member]
Inventories held on consignment			$ 0
Revenue, Performance obligation, Description of payment terms			The terms of payment over the recognized receivables from distributors are less than one year, and therefore these sales do not have any significant financing components.
Revenue, Performance obligation, Funds collected at the time of subscription			$ 0
Revenue, Performance obligation, Costs collected at the time of cancelation or modification of subscription			$ 0
Sales Channel Directly To Consumer Subscription Sales [Member]
Revenue Recognition Percentage Of Sales Discount Offered			10%
Number of days within the date of purchase within which return or refund request must be submitted			60 days
Every 2 Months Subscription [Member] | Sales Channel Directly To Consumer Subscription Sales [Member]
Revenue, Performance obligation, Subcription timing allowed to customer			2 months
Every 3 Months Subscription [Member] | Sales Channel Directly To Consumer Subscription Sales [Member]
Revenue, Performance obligation, Subcription timing allowed to customer			3 months
Every 4 Months Subscription [Member] | Sales Channel Directly To Consumer Subscription Sales [Member]
Revenue, Performance obligation, Subcription timing allowed to customer			4 months
Amazon [Member] | Sales Channel Directly To Consumer Subscription Sales [Member] | Maximum [Member]
Revenue Recognition Percentage Of Sales Discount Offered			10%
Amazon [Member] | Sales Channel Directly To Consumer Subscription Sales [Member] | Minimum [Member]
Revenue Recognition Percentage Of Sales Discount Offered			5%
Amazon [Member] | Sales Channel Directly To Consumer Subscription Sales [Member] | Weighted Average [Member]
Revenue Recognition Percentage Of Sales Discount Offered			6%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Concentrations of Risk (Details) - Customer Concentration Risk [Member]	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
iHerb, Inc. | Accounts Receivable
Product Information [Line Items]
Concentration risk percentage			12.10%		41.30%
iHerb, Inc. | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration risk percentage		17.50%		15.30%
Emerson Ecologics, LLC | Accounts Receivable
Product Information [Line Items]
Concentration risk percentage			26.10%		33.30%
Emerson Ecologics, LLC | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration risk percentage		12.50%		12.30%
Pattern Inc. | Accounts Receivable
Product Information [Line Items]
Concentration risk percentage			18.50%
Pattern Inc. | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration risk percentage	36.70%	25.10%	34.20%	28.30%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Revenue Disaggregated by Geography (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Amount	$ 56,067,826	$ 42,889,965	$ 110,736,024	$ 87,373,705
Percent of Total	100%	100%	100%	100%
Domestic Member [Member]
Disaggregation of Revenue [Line Items]
Amount	$ 52,542,648	$ 40,845,805	$ 105,058,997	$ 82,725,091
Percent of Total	93.70%	95.20%	94.90%	94.70%
Foreign Member [Member]
Disaggregation of Revenue [Line Items]
Amount	$ 3,525,178	$ 2,044,160	$ 5,677,027	$ 4,648,614
Percent of Total	6.30%	4.80%	5.10%	5.30%

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Revenues Based Upon Sales Channel (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Amount	$ 56,067,826	$ 42,889,965	$ 110,736,024	$ 87,373,705
Percent of Total	100%	100%	100%	100%
Sales Channel Directly To Consumer Subscription Sales [Member]
Disaggregation of Revenue [Line Items]
Amount	$ 9,667,533	$ 5,546,028	$ 18,015,429	$ 11,026,552
Percent of Total	17.20%	12.90%	16.30%	12.60%
Sales Channel Directly To Consumer Transaction Sales [Member]
Disaggregation of Revenue [Line Items]
Amount	$ 19,214,981	$ 11,486,170	$ 36,677,282	$ 25,409,646
Percent of Total	34.30%	26.80%	33.10%	29.10%
Sales Channel Professional Business To Business Sales [Member]
Disaggregation of Revenue [Line Items]
Amount	$ 27,185,312	$ 25,857,767	$ 56,043,313	$ 50,937,507
Percent of Total	48.50%	60.30%	50.60%	58.30%

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)												3 Months Ended			6 Months Ended
	Oct. 04, 2021 USD ($)	Apr. 26, 2021 USD ($)	Apr. 21, 2021 USD ($)	Feb. 12, 2021 USD ($)	Jan. 06, 2021 shares	Oct. 16, 2020 USD ($) Number	Feb. 14, 2020 USD ($)	Dec. 03, 2019	Mar. 19, 2019 USD ($)	Feb. 28, 2019 USD ($)	Jul. 05, 2018 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Oct. 29, 2021 USD ($)	Sep. 22, 2021 shares	Mar. 03, 2021	Dec. 31, 2020 USD ($)	Dec. 03, 2018 USD ($)	Nov. 30, 2018 USD ($)
Related Party Transaction [Line Items]
Agreement extending									one year
Revenues												$ 56,067,826	$ 42,889,965		$ 110,736,024	$ 87,373,705
Related party payable												874,870			874,870		$ 1,634,775
Repayments of related party payable												43,000			43,000
Related party receivables												32,685			32,685		366,590
Other related party receivables												151,300			151,300		0
Restricted Cash												4,900,000			$ 4,900,000		4,900,000
Non controlling interests of the acquiree asset acquistion			$ 200,000
Drawbridge Health Inc [Member]
Related Party Transaction [Line Items]
Equity method investment net													3,200,000	$ 3,200,000		3,200,000					$ 3,400,000
Non controlling interests of the acquiree asset acquistion		$ 209,592
Merger Agreement [Member] | Drawbridge Health Inc [Member]
Related Party Transaction [Line Items]
Ownership interest			76.30%
Variable Interest Entity Ownership Percentage		11.20%	11.20%
Equity method investment ownership percentage			76.30%
Equity method investment percentage acquired		76.30%	87.50%												87.50%
Payment for net asset acquistion		$ 1,400,000
Mitsui Secondment Agreement [Member]
Related Party Transaction [Line Items]
Related party payable												30,000			$ 30,000		30,000
Registration Rights Agreement [Member]
Related Party Transaction [Line Items]
Cost incurred associated with registration for issuance of shares												0			0
Onegevity Merger [Member]
Related Party Transaction [Line Items]
Shares, Outstanding | shares					5,712
Variable Interest Entity Ownership Percentage					4%
Onegevity Merger [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Ownership interest																				4.40%
Equity method investment ownership percentage																				4.40%
Kirin Holdings Company Limited [Member]
Related Party Transaction [Line Items]
Preferred Stock Shares Issued and Sold | shares											27,011,500
Purchase price | $ / shares											$ 5.12
Gross Proceeds from Issuance of Convertible Preferred Stock											$ 138,400,000
Series E convertible preferred stock converted into common stock | shares																			27,011,500
Kirin Holdings Company Limited [Member] | Juntendo Agreement [Member]
Related Party Transaction [Line Items]
DNA Services Samples | Number						600
Proceeds from DNA Sample Services						$ 129,000
Revenues												16,000	7,000		16,000	15,000
Receivables												16,000			16,000		0
Kirin and Mitsui [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party																20,000,000
Employment related expense												30,000
Annual fee				$ 20			$ 20,000,000
Percentage Of Annual Fee				1.20%			2%
Line of Credit Facility, Maximum Amount Outstanding During Period				$ 20,000,000			$ 20,000,000
Repayments Of Lines Of Credit	$ 20,000,000
Letter of Credit Guarantee																							$ 4.9
Kirin and Mitsui [Member] | Revolving Credit Facility [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party																4,900,000
Letter of credit Reimbursement																							4,900,000
Annual fee																							$ 4,900,000
Security Deposit, Letter of credit																						$ 4,900,000
Letter of credit expiration date								Dec. 03, 2019
Restricted interest-bearing account																		$ 4,900,000
Restricted Cash												4,900,000			$ 4,900,000		4,900,000
Line of Credit Facility, Maximum Amount Outstanding During Period							$ 20,000,000
Kirin and Mitsui [Member] | Feasibility Review Agreement [Member]
Related Party Transaction [Line Items]
Ownership interest									5%
Feasibility commercialization Amount									$ 500,000
Equity method investment ownership percentage									5%
Equity securities issued | shares															0
Kirin and Mitsui [Member] | Mitsui Secondment Agreement [Member]
Related Party Transaction [Line Items]
Services										$ 120,000
Employment related expense													30,000	$ 30,000	$ 60,000	60,000
Kirin and Mitsui [Member] | Guarantee Fees Expenses [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party													100,000			200,000
Kirin and Mitsui [Member] | Guarantee Fees Expenses [Member] | Revolving Credit Facility [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party													41,000			100,000
Kirin Secondment Agreement [Member]
Related Party Transaction [Line Items]
Related party payable												21,000			21,000		21,000
Employment related expense												21,000	21,000		42,000	42,000
Kirin and Kyowa Hakko Bio [Member]
Related Party Transaction [Line Items]
Revenues												100,000			100,000
Related party payable												19,000			19,000
Kirin Client [Member]
Related Party Transaction [Line Items]
Revenues												26,000			26,000
Receivables												$ 8,000			$ 8,000
NR Therapeutics, LLC [Member]
Related Party Transaction [Line Items]
Ownership interest												49%			49%
Equity method investment ownership percentage												49%			49%
NR Therapeutics, LLC [Member] | Purchases Of Inventory [Member]
Related Party Transaction [Line Items]
Related party payable												$ 800,000			$ 800,000		200,000
Related Party Transaction, Purchases from Related Party												1,500,000	1,800,000		1,800,000	2,800,000
Tecton Group LLC [Member]
Related Party Transaction [Line Items]
Related party receivables												0			0		0
Purchase of investment in equity-method investments																500,000
Nutrativa LLC [Member]
Related Party Transaction [Line Items]
Related party receivables																	400,000
Revenue from Related Parties													32,000			47,000
Oova Inc [Member]
Related Party Transaction [Line Items]
Related party receivables												8,000			8,000		$ 2,000
Revenue from Related Parties												24,000	$ 7,000		27,000	$ 11,000
Chief Technology Officer [Member]
Related Party Transaction [Line Items]
Other related party receivables												$ 151,000			$ 151,000
Combined Thorne [Member] | Onegevity Merger [Member]
Related Party Transaction [Line Items]
Outstanding Equity Percentage																				14.10%

Mergers and Acquisitions -Summa

Mergers and Acquisitions -Summary of the Assets and Liabilities Acquired Based on Their Fair Value (Detail) - USD ($)	Apr. 26, 2021	Apr. 21, 2021
Asset Acquisition [Line Items]
Less: noncontrolling interest		$ (200,000)
Drawbridge Health Inc [Member]
Asset Acquisition [Line Items]
Cash	$ 11,823
Accounts receivable	8,686
Prepaid expenses and other current assets	711,389
Inventories	10,051
Property and equipment	914,716
Operating lease right-of-use asset	410,732
Intangible asset consisting of in process research and development	1,563,015
Other assets	22,782
Accounts payable	701,242
Other accrued expenses	864,483
Current portion of operating lease obligations	263,509
Long term operating lease, net of current portion	147,223
Net assets acquired	1,676,737
Less: noncontrolling interest	(209,592)
Net assets acquired by Thorne HealthTech, Inc.	$ 1,467,145

Mergers and Acquisitions - Sche

Mergers and Acquisitions - Schedule of Recognized Identifiable Tangible and Intangible Assets Acquired and Liabilities assume (Details) - Nutrativa LLC Acquisition [Member]	Feb. 28, 2022 USD ($)
Business Combination And Asset Acquistion [Line Items]
Cash	$ 17,713
Accounts receivable	14,740
Inventories, net	274
Property and equipment, net	3,256,996
Intangible assets, net	10,200,000
Goodwill	2,100,358
Accounts payable	(181,913)
Other accrued expenses	(203)
Net assets acquired by Thorne HealthTech, Inc.	$ 15,407,965

Mergers and Acquisitions - Addi

Mergers and Acquisitions - Additional Information (Detail) - USD ($)					3 Months Ended		6 Months Ended		9 Months Ended
	Feb. 28, 2022	Apr. 26, 2021	Apr. 21, 2021	Jan. 06, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Business Combination And Asset Acquistion [Line Items]
Non controlling interests of the acquiree asset acquistion			$ 200,000
Loss On Drawbridge Transaction					$ 0	$ 165,998	$ 0	$ 165,998
In process research and developments costs written off acquired other than through business combination							$ 0	1,563,015
Onegivity Health Inc [Member]
Business Combination And Asset Acquistion [Line Items]
Equity method investment ownership percentage											50%
Business combination stock options issued to the the key managers of the acquiree in a tax free exchange shares				1,959,335
Onegivity Health Inc [Member] | Common Class B [Member]
Business Combination And Asset Acquistion [Line Items]
Business combination equity interests issued number of shares				6,179,270
Onegivity Health Inc [Member] | Noncontrolling Interest [Member] | Common Class B [Member]
Business Combination And Asset Acquistion [Line Items]
Business combination equity interests issued number of shares				472,590
Drawbridge Health Inc [Member]
Business Combination And Asset Acquistion [Line Items]
Equity method investment net						3,200,000		3,200,000		$ 3,200,000	$ 3,400,000
Non controlling interests of the acquiree asset acquistion		$ 209,592
Drawbridge Health Inc [Member] | Net Asset Acquistion Of Drawbridge Investments [Member]
Business Combination And Asset Acquistion [Line Items]
Loss On Drawbridge Transaction						200,000		200,000
In process research and developments costs written off acquired other than through business combination						$ 1,600,000		$ 1,600,000
Non controlling interests ownership percentage by the non controlling owners					12.50%		12.50%
Drawbridge Health Inc [Member] | Net Asset Acquistion Of Drawbridge Investments [Member] | Other Nonoperating Income (Expense) [Member]
Business Combination And Asset Acquistion [Line Items]
Gain loss on asset acquistion		$ 200,000
Drawbridge Health Inc [Member] | Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]
Business Combination And Asset Acquistion [Line Items]
Impairment loss on equity method investments									$ 3,000,000
Drawbridge Health Inc [Member] | Merger Agreement [Member]
Business Combination And Asset Acquistion [Line Items]
Equity method investment ownership percentage			76.30%
Equity method investment ownership percentage in variable interest entity		11.20%	11.20%
Equity method investment percentage acquired		76.30%	87.50%				87.50%
Payment for net asset acquistion		$ 1,400,000
Nutrativa LLC Acquisition [Member]
Business Combination And Asset Acquistion [Line Items]
Total transaction costs					$ 100,000		$ 500,000
Consideration provided to the unit-holders	$ 15,400,000
Payments to acquired businesses gross	14,900,000
Amount due to the Company	500,000
Cash Acquired	$ 18,000

Consolidated Variable Interes_3

Consolidated Variable Interest Entities (Additional Information) (Details) - USD ($) $ in Millions	Jan. 01, 2021	Jun. 30, 2022	Jan. 10, 2022
Mitsui Co. Ltd. [Member]
Variable Interest Entity [Line Items]
Total issued shared capital contribution			$ 2.6
Non-controlling interest ownership percentage		49%
Onegevity Health, LLC [Member]
Variable Interest Entity [Line Items]
Shares Owned, Increase in Number of Shares	58,252
Variable Interest Entity Ownership Percentage	50%
Thorne Asia JV
Variable Interest Entity [Line Items]
Total issued shared capital contribution			$ 2.7
Non-controlling interest ownership percentage		51%

Consolidated Variable Interes_4

Consolidated Variable Interest Entities - Schedule of Variable Interest Entities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Variable Interest Entity [Line Items]
Assets	$ 189,386,333		$ 189,386,333		$ 175,299,877
Net sales	56,067,826	$ 42,889,965	110,736,024	$ 87,373,705
Net income (loss)	(5,767,243)	(333,291)	(1,056,002)	4,373,199
Net loss-non-controlling interests	(176,538)	(245,061)	(444,356)	(245,061)
Net loss attributable to Thorne HealthTech, Inc.	(5,590,705)	$ (88,230)	(611,646)	$ 4,618,260
Thorne Asia JV
Variable Interest Entity [Line Items]
Assets	4,636,316		4,636,316
Less: Total labilities	31,394		31,394
Net assets (liabilities )	4,604,922		4,604,922
Net sales	10,599		16,491
Net income (loss)	(175,482)		(546,793)
Net loss-non-controlling interests	(85,986)		(267,929)
Net loss attributable to Thorne HealthTech, Inc.	$ (89,496)		$ (278,864)

Inventories, Net - Summary of I

Inventories, Net - Summary of Inventories (Detail) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Inventory [Line Items]
Raw materials	$ 33,839,020	$ 22,620,773
Work in process	165,870	422,196
Finished goods	27,068,958	18,413,853
Reserve for slow moving and obsolete inventory	(602,380)	(444,698)
Inventories, net	$ 60,471,468	$ 41,012,124

Property and Equipment, Net - C

Property and Equipment, Net - Components of Property and Equipment (Detail) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 40,379,181	$ 36,107,408
Less, accumulated depreciation and amortization	(12,373,904)	(11,262,651)
In-process assets, including deposits on new equipment	2,759,129	2,185,643
Property and equipment, net	30,764,406	27,030,400
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	13,914,862	9,937,510
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property and equipment	509,054	491,173
Office equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	777,215	1,111,141
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	19,565,760	19,431,916
Vehicles
Property, Plant and Equipment [Line Items]
Total property and equipment	98,282	98,282
Lab equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	2,938,346	2,930,059
Purchased software
Property, Plant and Equipment [Line Items]
Total property and equipment	2,150,051	2,107,327
Internally-developed software
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 425,611	$ 0

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Line Items]
In process assets, Depreciation			$ 0
Depreciation and amortization expense	$ 900,000	$ 800,000	$ 1,800,000	$ 1,400,000

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Feb. 28, 2022	Dec. 31, 2021	Jun. 30, 2010
Restructuring Cost and Reserve [Line Items]
Amortization of Intangible Assets	$ 700,000	$ 500,000	$ 1,100,000	$ 900,000
Goodwill							$ 14,400,000
Payments under license agreements, Intangible Assets	16,089,408		16,089,408			$ 6,592,316
Intangible assets Acquired from acquisition	14,500,000		14,500,000			5,000,000
Finite-Lived Intangible Assets, Net	16,089,408		16,089,408			6,592,316
Nutrativa LLC Acquisition [Member]
Restructuring Cost and Reserve [Line Items]
Goodwill					$ 2,100,000
Trade names
Restructuring Cost and Reserve [Line Items]
Payments under license agreements, Intangible Assets	1,520,000		1,520,000			1,773,333
Finite-Lived Intangible Assets, Net	1,520,000		1,520,000			1,773,333
Reduction in carrying amount of intangible assets			1,000,000
Reduction in accumulated amortization			1,000,000
Existing technology/reformulations
Restructuring Cost and Reserve [Line Items]
Payments under license agreements, Intangible Assets	10,427,500		10,427,500			513,333
Finite-Lived Intangible Assets, Net	10,427,500		10,427,500			513,333
Reduction in carrying amount of intangible assets			1,000,000
Reduction in accumulated amortization			1,000,000
Research and development formulas
Restructuring Cost and Reserve [Line Items]
Payments under license agreements, Intangible Assets						0
Finite-Lived Intangible Assets, Net						0
Reduction in carrying amount of intangible assets			800,000
Reduction in accumulated amortization			800,000
License agreements
Restructuring Cost and Reserve [Line Items]
Payments under license agreements, Intangible Assets	1,541,908		1,541,908			1,543,150
Finite-Lived Intangible Assets, Net	$ 1,541,908		1,541,908			$ 1,543,150
Reduction in carrying amount of intangible assets			6,200,000
Reduction in accumulated amortization			$ 6,200,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of goodwill carrying amount during the year (Details)	6 Months Ended
	Jun. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance	$ 14,440,683
Acquisitions	2,100,358
Goodwill, Ending Balance	$ 16,541,041

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 29,254,002	$ 27,739,745
Accumulated Amortization	(13,164,594)	(21,147,429)
Finite-Lived Intangible Assets, Net, Total	16,089,408	6,592,316
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	6,500,000	6,500,000
Accumulated Amortization	(3,900,000)	(3,737,500)
Finite-Lived Intangible Assets, Net, Total	2,600,000	2,762,500
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	7,600,000	8,640,000
Accumulated Amortization	(6,080,000)	(6,866,667)
Finite-Lived Intangible Assets, Net, Total	1,520,000	1,773,333
Existing technology/reformulations
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	12,400,000	3,207,923
Accumulated Amortization	(1,972,500)	(2,694,590)
Finite-Lived Intangible Assets, Net, Total	10,427,500	513,333
Research and development formulas
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value		800,000
Accumulated Amortization		(800,000)
Finite-Lived Intangible Assets, Net, Total		0
License agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	2,754,002	8,591,822
Accumulated Amortization	(1,212,094)	(7,048,672)
Finite-Lived Intangible Assets, Net, Total	$ 1,541,908	$ 1,543,150

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2022	$ 1,306,033
2023	2,391,234
2024	2,080,817
2025	1,551,026
2026	1,208,734
Thereafter	7,551,564
Finite-Lived Intangible Assets, Net, Total	$ 16,089,408	$ 6,592,316

Investments (Additional Informa

Investments (Additional Information) (Details) $ in Millions	Jan. 07, 2022 USD ($)
Heart-Tech Health, Inc
Net Investment Income [Line Items]
Equity securities invested	$ 1

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)						3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 08, 2022	Oct. 29, 2021	Oct. 04, 2021	Feb. 12, 2021	Feb. 14, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2018
Line of Credit Facility [Line Items]
Equipment Collateralized by Notes Payables						$ 1,700,000		$ 1,700,000
Debt Instrument Covenant Leverage Ratio Maximum	2.5
Debt Instrument FCCRE Leverage Ratio Minimum	1.25
Guarantee fees						0	$ (140,407)	0	$ (279,271)
Amount Not Drawn Under Loan Agreement						$ 15,000,000		$ 15,000,000
Credit Agreements [Member] | Sumitomo Mitsui Banking Corporation [Member]
Line of Credit Facility [Line Items]
Guarantee Fee Expense							100,000		200,000
Twenty Twenty and Twenty Twenty One Credit Agreement [Member] | Sumitomo Mitsui Banking Corporation [Member]
Line of Credit Facility [Line Items]
Percentage of share holder guaranteed on total loan amount								50%
Guarantee Amount				$ 10,000,000
Twenty Twenty One Credit Agreement [Member]
Line of Credit Facility [Line Items]
Repayments of Long-term Debt			$ 20,000,000
Repayment Of Debt Incremental Fees			$ 7
Twenty Twenty One Credit Agreement [Member] | Sumitomo Mitsui Banking Corporation [Member]
Line of Credit Facility [Line Items]
Percentage of Guarantee Fee on Outstanding Borrowings				1.20%	2%
Standby Letters of Credit [Member] | Sumitomo Mitsui Banking Corporation [Member]
Line of Credit Facility [Line Items]
Line of credit facility, guarantee fee		$ 4,900,000
Guarantee Fee Expense							$ 41,000		$ 100,000
Standby Letters of Credit [Member] | Guarantee Fees [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Commitment Fee Percentage										50%
Standby Letters of Credit [Member] | Guarantee Fees [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Expiration Date										Dec. 03, 2019
Line of Credit Facility Renewal Date										Oct. 31, 2037
Line of Credit Facility, Expiration Period										12 months
Line of Credit Facility, Commitment Fee Percentage										3%
Long-term line of credit										$ 4,900,000
Line of credit facility annual fees amount										$ 20,000
Commercial and Standby Letters of Credit [Member]
Line of Credit Facility [Line Items]
Long-term line of credit	$ 6,000,000
Loan Agreement [Member]
Line of Credit Facility [Line Items]
Unused Commitment Fee Percentage	0.20%
Long-term line of credit	$ 15,000,000
Interest rate adjusted with variable rate	1.50%
Variable interest rate	6%

Debt - Schedule of Long-term De

Debt - Schedule of Long-term Debt (Detail) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-Term Debt, Gross	$ 1,334,332	$ 1,577,807
Less: Current portion of long-term debt	(508,844)	(494,173)
Long-term Debt	825,488	1,083,634
Notes payable Fixed interest 5.44, Maturity Due September 10, 2026 [Member]
Debt Instrument [Line Items]
Long-Term Debt, Gross	374,888	413,574
Notes payable Fixed interest 4.89, Maturity Due March 20, 2025 [Member]
Debt Instrument [Line Items]
Long-Term Debt, Gross	578,686	675,836
Notes payable Fixed interest 6.943, Maturity Due August 12, 2024 [Member]
Debt Instrument [Line Items]
Long-Term Debt, Gross	233,908	286,255
Notes payable Fixed interest 6.943, Maturity Due July 15, 2023 [Member]
Debt Instrument [Line Items]
Long-Term Debt, Gross	$ 146,850	$ 202,142

Debt - Schedule of Long-term _2

Debt - Schedule of Long-term Debt (Parenthetical) (Detail)	6 Months Ended
	Jun. 30, 2022 USD ($)
Notes payable Fixed interest 6.943, Maturity Due August 12, 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment	$ 30,917
Debt Instrument, Interest Rate, Stated Percentage	6.94%
Debt Instrument, Maturity Date	Aug. 12, 2024
Notes payable Fixed interest 6.943, Maturity Due July 15, 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment	$ 30,917
Debt Instrument, Interest Rate, Stated Percentage	6.94%
Debt Instrument, Maturity Date	Jul. 15, 2023
Notes payable Fixed interest 4.89, Maturity Due March 20, 2025 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment	$ 56,548
Debt Instrument, Interest Rate, Stated Percentage	4.89%
Debt Instrument, Maturity Date	Mar. 20, 2025
Notes payable Fixed interest 5.44, Maturity Due September 10, 2026 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment	$ 8,250
Debt Instrument, Interest Rate, Stated Percentage	5.44%
Debt Instrument, Maturity Date	Sep. 10, 2026

Leases - Summary of Operating a

Leases - Summary of Operating and Finance Leases (Detail) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Operating lease:
Operating lease right-of-use assets, net	$ 16,203,487	$ 17,836,756
Current portion of operating lease liabilities	1,599,190	2,633,236
Operating lease liabilities, net of current portion	27,026,923	27,605,739
Total operating lease liabilities	28,626,113	30,238,975
Finance lease:
Finance lease right-of-use assets	716,402	883,076
Current portion of finance lease liabilities	391,003	413,487
Finance lease liabilities, net of current portion	348,352	482,544
Total finance lease liabilities	$ 739,355	$ 896,031

Leases - Summary of Lease Expen

Leases - Summary of Lease Expense (Detail) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Operating lease:
Operating lease cost	[1]	$ 1,461,356	$ 1,369,459	$ 2,922,711	$ 2,602,167
Finance lease:
Amortization of leased assets		107,112	94,418	219,512	168,333
Interest on lease liabilities		10,459	13,748	22,047	25,048
Total lease cost.		$ 1,578,927	$ 1,477,625	$ 3,164,270	2,795,548
Weighted average remaining lease term (years)
Operating leases		13 years 11 months 4 days		13 years 11 months 4 days		13 years 8 months 23 days
Finance leases		2 years 3 days		2 years 3 days		2 years 3 months 29 days
Operating leases		8.90%		8.90%		9.20%
Finance leases		5.90%		5.90%		6.10%
Operating cash outflows from operating leases				$ 2,902,305	3,244,257
Operating cash outflows from finance leases (interest payments)				22,047	25,048
Financing cash outflows from finance leases				209,514	171,734
Leased assets obtained in exchange for finance lease liabilities				52,838	420,361
Leased assets obtained in exchange for operating lease liabilities				$ 0	$ 2,913,002
[1] Includes short-term leases and variable lease costs, which are immaterial.

Leases - Summary of Maturities

Leases - Summary of Maturities of Operating and Finance Lease Liabilities (Detail) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Lessee Lease Liabilities Payments Due [Abstract]
2022	$ 2,218,628
2023	3,497,422
2024	3,589,920
2025	3,559,583
2026	3,325,639
Thereafter	35,705,779
Total lease payments	51,896,971
Less: imputed interest	23,270,858
Total operating lease liabilities	28,626,113	$ 30,238,975
Less: current portion of lease liabilities	1,599,190	2,633,236
Long-term portion of lease liabilities	27,026,923	27,605,739
Remainder of 2022	233,900
2023	343,422
2024	157,455
2025	22,189
2026	38,944
Thereafter	0
Finance Lease, Liability, Payment, Due, Total	795,910
Less: imputed interest	56,555
Total finance lease liabilities	739,355	896,031
Less: current portion	391,003	413,487
Long-term portion of lease liabilities	$ 348,352	$ 482,544

Leases - Additional Information

Leases - Additional Information (Detail) $ in Millions		6 Months Ended
	Jul. 28, 2021 USD ($) ft²	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jan. 26, 2021 ft²
Minimum [Member]
Lessee, Operating lease, Term of contract		1 year
Maximum [Member]
Lessee, Operating lease, Term of contract		30 years
Summerville South Carolina warehouse
Maximum Allowance For Tenant Improvements	$ 1.3
Area of land | ft²	360,320
Lessee, Operating lease, Renewal term	5 years
Annual Base Rent	$ 2
Lease esclation percent	2%
Customary security deposit		$ 0.3	$ 0.3
S C
Lease Expiration Term				2026-07
Lessee, Operating lease, Term of contract				5 years
Lessee, Operating lease, Renewal term				3 years
Line of credit facility, guarantee fee		4.9
Customary security deposit		$ 0.1	$ 0.1
S C | Minimum [Member]
Area of land | ft²				115,500
S C | Maximum [Member]
Area of land | ft²				136,500

Convertible Preferred Stock a_2

Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail) - USD ($) $ in Millions	Sep. 22, 2021	Jul. 05, 2018	Jun. 30, 2022	Dec. 31, 2021
Statement [Line Items]
Common Stock, Shares, Outstanding			52,733,269	52,554,214
Series E Convertible Preferred Stockmember [Member]
Statement [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		27,011,500
Common Stock, Conversion Basis	one-to-one
Common Stock, Shares, Outstanding	27,011,500
Temporary Equity, Shares Outstanding			0	0
Preferred Stock, Value, Subscriptions		$ 138.4

Warrants - Schedule of Fair Val

Warrants - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Detail)	Jun. 30, 2022	Dec. 31, 2021
Fair Market Value [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	4.84	6.21
Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	6.74	6.74
Term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	8	8.5
Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	75	75
Annual Dividend [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input
Risk-free interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	3.01	1.48

Warrants - Summary of Assets an

Warrants - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 1,529,586	$ 2,058,566
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	1,529,586	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 0	$ 2,058,566

Warrants - Summary of Change in

Warrants - Summary of Change in the Fair Value of Derivative Warrant Liabilities (Detail) - USD ($)	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Transfer to Level 2	$ (2,124,485)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance		$ 2,058,566
Change in fair value of warrant liability		$ 65,919
Balance	$ 0

Warrants - Additional Informati

Warrants - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions			1 Months Ended
	Oct. 10, 2018	Jun. 23, 2010	Jul. 31, 2020	Jun. 30, 2022	Dec. 31, 2021	May 10, 2011
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				4,450,000	4,450,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.12
Class of Warrant or Right, Expired date of Warrants or Rights	Oct. 11, 2028
Proceeds from Issuance of Warrants			$ 22.2
Class of Warrant or Right, Outstanding				113,030	113,030
Warrants, Fair Value Disclosure				$ 1.5	$ 2.1
Equity Based Warrants [Member]
Class of Warrant or Right, Warrants Exercised			2,168,485
Common Stock Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,532,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 6.74
Class of Warrant or Right, Expired date of Warrants or Rights		Jun. 23, 2020
Class of Warrant or Right, Outstanding				2,532,000	2,532,000
Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	4,450,000					453,455
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 6.74
Common Stock [Member] | Shareholders One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,225,000

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Stock-based compensation expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 3,141,836	$ 24,143	$ 5,151,248	$ 534,665
Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	237,786	24,143	475,572	534,665
Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 2,904,050	$ 0	$ 4,675,676	$ 0

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule Of Share Based Compensation Arrangements By Share Based Payment Award (Detail) - Stock Option Activity [Member]	6 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares		Dec. 31, 2021 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options Issued and Outstanding, Opening balance | shares	9,699,656
Options Issued and Outstanding, Granted | shares
Options Issued and Outstanding, Exercised | shares	(179,055)
Options Issued and Outstanding, Cancelled/forfeited | shares
Options Issued and Outstanding, Closing balance | shares	9,520,601		9,699,656
Vested and expected to vest after June 30, 2022 | shares	9,520,601
Options Issued and Outstanding, Exercisable | shares	1,690,381
Weighted- Average Exercise Price, Opening balance | $ / shares	$ 5.28
Weighted- Average Exercise Price, Granted | $ / shares	0
Weighted- Average Exercise Price, Exercised | $ / shares	1.36
Weighted- Average Exercise Price, Cancelled/forfeited | $ / shares	0
Weighted- Average Exercise Price, Closing balance | $ / shares	5.35		$ 5.28
Vested and expected to vest after June 30, 2022 | $ / shares	5.35
Weighted- Average Exercise Price, Exercisable | $ / shares	$ 2.71
Weighted Average Remaining Contractual Term (Years), Outstanding, Opening Balance			6 years 2 months 19 days
Weighted Average Remaining Contractual Term (Years), Outstanding, Closing Balance	5 years 6 months 29 days
Vested and expected to vest after June 30, 2022	5 years 6 months 29 days
Weighted Average Remaining Contractual Term (Years), Outstanding, Exercisable	2 years 5 months 1 day
Aggregate Intrinsic Value opening, Outstanding | $	$ 12.3	[1]
Aggregate Intrinsic Value opening, Outstanding | $	3.6	[1]	$ 12.3	[1]
Vested and expected to vest after June 30, 2022 | $	3.6	[1]
Aggregate Intrinsic Value, Outstanding, Exercisable | $	$ 3.6	[1]
[1] (1) Aggregate intrinsic value is presented in millions of U.S. dollars and represents the difference between the closing fair value of the underlying common stock and the exercise price of outstanding, in-the-money options on the date of measurement.

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule Of Additional Information on Stock Options Outstanding (Details) - USD ($)		3 Months Ended	6 Months Ended
		Jun. 30, 2022	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Intrinsic value of stock options exercised	[1]	$ 8,133	$ 857,460
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value of stock options granted	[2]	$ 6.91	$ 6.91
[1] (3) Shares of the Company’s common stock, traded under the symbol “THRN,” have been publicly traded since September 23, 2021, when the Company’s common stock was listed and began trading on the Nasdaq Global Select Market (the “Nasdaq”). No market for the Company’s stock existed prior to September 23, 2021. There were no stock option exercises prior to the IPO date. (1) The three and six months ended June 30, 2021 excludes 472,590 R SUs issued in exchange for outstanding profits interest units held by employees of Onegevity, in connection with the merger. The RSU exchange was determined to be materially a “like-for-like” transaction and there was no incremental stock compensation expense recorded by the Company. The Company compared the fair value of the RSUs immediately before and after the exchange and determined that the exchange did not result in incremental compensation expense.

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Non Vested Restricted Stock Shares Activity (Detail) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of Shares Outstanding, Opening balance | shares	3,406,760
Number of Shares Outstanding, Granted | shares	2,217,248
Number of Shares Outstanding, Released | shares	0
Number of Shares Outstanding, Cancelled/forfeited | shares	(5,000)
Number of Shares Outstanding, Ending balance | shares	5,619,008
Number of Shares Outstanding, Vested and expected | shares	5,619,008
Weighted- Average Grant-Date Fair Value, Opening balance | $ / shares	$ 9.82
Weighted- Average Grant-Date Fair Value, Granted | $ / shares	6.91
Weighted- Average Grant-Date Fair Value, Released | $ / shares	0
Weighted- Average Grant-Date Fair Value, Cancelled/forfeited | $ / shares	8.40
Weighted- Average Grant-Date Fair Value, Ending balance | $ / shares	8.67
Weighted- Average Grant-Date Fair Value, Vested and expected | $ / shares	$ 8.67

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)		3 Months Ended		6 Months Ended
	Sep. 23, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jan. 26, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 200,000		$ 200,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition				3 months
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		0	0	0	0
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of Shares Outstanding, Released				0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period				2,217,248
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		0	0	0	0
Onegivity Plan [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross			1,959,335		1,959,335
Incremental stock compensation expense			$ 0		$ 0
Onegivity Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross		472,590		472,590
Incremental stock compensation expense			$ 0		$ 0
Two Thousand And Twenty One Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 42,300,000		$ 42,300,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition				3 years 7 months 6 days
Two Thousand And Twenty One Plan [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance						2,627,710
Shares available for issuance under the 2021 Plan		1,359,972		1,359,972

Basic and Diluted Earnings (L_2

Basic and Diluted Earnings (Loss) per Share - Schedule of the Calculate Net Income (loss) Per Share (Detail) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income (loss) attributable to Thorne HealthTech, Inc.		$ (5,590,705)	$ (88,230)	$ (611,646)	$ 4,618,260
Undistributed earnings (loss) attributable to Series E convertible preferred stockholders		0	(88,230)	0	4,618,260
Numerator for basic earnings (loss) per share-net income (loss) available to Thorne HealthTech, Inc. common stockholders (A)		(5,590,705)	0	(611,646)	0
Undistributed earnings (loss) attributable to Series E convertible preferred stockholders-diluted		0	88,230	0	(4,618,260)
Numerator for diluted earnings (loss) per share-net income (loss) available to Thorne HealthTech, Inc. common stockholders (C)		$ (5,590,705)	$ 0	$ (611,646)	$ 0
Weighted average number of common shares outstanding – basic	[1]	52,731,604	17,650,035	52,648,653	17,650,035
Denominator for basic earnings (loss) per share-weighted average shares (B)	[1]	52,731,604	17,650,035	52,648,653	17,650,035
Denominator for diluted earnings (loss) per share-adjusted weighted average common stock and common stock equivalents (D)	[1]	52,731,604	17,650,035	52,648,653	17,650,035
Basic earnings (loss) per share (A/B)	[1]	$ 0.11	$ 0	$ 0.01	$ 0
Diluted earnings (loss) per share (C/D)	[1]	$ 0.11	$ 0	$ 0.01	$ 0
[1] For the three and six months ended June 30, 2022, 18.1 million and 17.2 million warrants and stock-based awards, respectively, were excluded from the computation of diluted earnings (loss) per share because the effect would have been anti-dilutive under the treasury stock method

Basic and Diluted Earnings (L_3

Basic and Diluted Earnings (Loss) per Share - Schedule of the Calculate Net Income (loss) Per Share (Parenthetical) (Detail) - shares shares in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Warrants And Stockbased Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share	18.1	17.2

Basic and Diluted Earnings (L_4

Basic and Diluted Earnings (Loss) per Share - Additional Information (Detail)	Sep. 22, 2021 USD ($)
Earnings Per Share [Abstract]
Conversion of Series E convertible preferred stock to common stock	$ 27,011,500

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Annual Minimum Commitments (Detail)	Jun. 30, 2022 USD ($)
Other Commitments [Line Items]
Remainder of 2022	$ 415,000
2023	562,500
Total	$ 977,500

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2017
SEYCHELLES | Grant
Other Commitments [Line Items]
Regulated Operating Revenue, Other					$ 0.8
Period For Which The Performance Obligation Must Be Maintained					5 years
Royalty Agreement On Future Sales
Other Commitments [Line Items]
Payment of Royalties	$ 0.1	$ 0.2	$ 0.2	$ 0.2